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3Abstract
Anti-inflammatory therapies are promising candidates for the prevention of brain
injury following prolonged seizures (status epilepticus). Biomarkers for therapy
monitoring are needed to translate these recent findings to the clinic. The aim of this
thesis was to develop imaging methods that can be used to monitor anti-
inflammatory therapies and monitor disease progression following prolonged
seizures.
In order to achieve these goals, the lithium-pilocarpine model was used as a model of
status epilepticus and novel MRI imaging methods were employed. Various imaging
approaches including: quantitative, structural, molecular and functional imaging
were tested for their possible investigative utility as imaging biomarkers for
neuroprotective therapies. Alongside this, two different anti-inflammatory therapies
were tested for their effectiveness to alter brain injury following status epilepticus.
This thesis demonstrates that molecular imaging has potential to monitor
neuroprotective therapies. Surprisingly, there was little evidence that the anti-
inflammatory therapies tested here had beneficial effects. However, this thesis shows
that employing novel imaging approaches and automated analysis methods can
enable accurate in vivo assessment of disease altering therapies.
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Thesis Outline
The focus of this thesis is the development and application of novel imaging
approaches for the lithium-pilocarpine rat model of epilepsy. The emphasis is on the
identification of biomarkers for therapy monitoring. Chapter 1 discusses the current
state of epilepsy research, the processes involved in the development of epilepsy and
the need for animal models of epilepsy. Chapter 2 provides the theory behind
magnetic resonance imaging and the different imaging pulse sequences that are used
in this project. Chapter 3 outlines the development of experimental protocols and
image analysis methods. Chapter 4 describes the development and characterisation of
the iron oxide contrast agent that is used in molecular imaging studies. Chapter 5
details the application of this molecular imaging approach to the lithium-pilocarpine
model of prolonged seizures. Chapter 6 is split into three parts. The first part details
an attempt to use molecular imaging to monitor an anti-inflammatory therapy -
dexamethasone given after status epilepticus. The second part is concerned with
using imaging to assess whether or not dexamethasone is neuroprotective. The last
part is concerned with a different anti-inflammatory drug - ethyl pyruvate. Chapter 7
describes the use of functional MRI to observe network alterations following status
epilepticus and finally Chapter 8 summarises the conclusions that can be drawn from
this work and outlines potential future work.
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Chapter 1 Epilepsy
1.1 Classification
Epilepsy is a family of neurological disorders characterised by recurrent or the
potential for recurrent epileptic seizures. Typical definitions include three
elements(1): History of at least one seizure, enduring alteration of the brain that
increases the likelihood of future seizures and associated neurobiologic, cognitive,
psychological and social disturbances. Epileptic conditions are classified according
to seizure type and cause. Seizures can be classified as either partial or generalised(2),
where the former relates to epileptic activity that is localised in the brain e.g. one
cerebral hemisphere, and the latter refers to seizures in which activity involves both
cerebral hemispheres. Further classification of seizures includes the degree to which
consciousness is impaired. The term ‘simple’ refers to the case in which there is no
or little impairment and ‘complex’ refers to the situation in which consciousness is
perceptibly impaired.
1.2 Temporal Lobe Epilepsy
Temporal lobe epilepsy (TLE) is the most common type of epilepsy. Mesial temporal
lobe epilepsy (mTLE) involves the amygdala, hippocampus, parahippocampal gyrus,
piriform cortex, entorhinal cortex, perirhinal cortex and to a lesser extent the cerebral
cortex and thalamus(3). The most common structural abnormality in mTLE is
hippocampal sclerosis (HS), which involves neuronal loss and gliosis of the
hippocampus. It is unknown whether HS is a cause or a consequence of seizures and
longitudinal imaging studies have yielded conflicting results regarding a possible
causal link between seizures and progressive hippocampal atrophy(4-6). It is true that
surgical resection of the amygdala and hippocampus often leads to seizure control(7),
which indicates that these regions are frequently required for seizure initiation and/or
propagation.
1.3 Aetiology
TLE often begins after an identifiable cerebral insult such as febrile seizures,
prolonged seizures, hypoxia-ischemia or head injury. Febrile seizures are thought to
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be linked to the development of temporal lobe epilepsy. These are seizures that are
associated with fever in the absence of other precipitating events, such as central
nervous system infection or electrolytic imbalance(8). Febrile seizures are extremely
common with a prevalence between 3% and 8% in children up to 7 years of age(9). It
is currently unknown whether febrile seizures cause epilepsy, however some
evidence exists to suggest that prolonged seizures (status epilepticus) could initiate a
cascade of events which may lead to the development of TLE. Even in cases of
prolonged febrile convulsions or repeated seizures within the same day, the risk of
developing spontaneous seizures may be as low as 6%(10), suggesting that a ‘second
hit’ may be necessary to trigger epilepsy development(11).
1.4 Status Epilepticus
Status epilepticus (SE) is the most common medical neurological emergency in
children and is defined as a seizure persisting for longer than 30 minutes(12).
Uninterrupted convulsive status epilepticus (CSE) is thought to cause brain injury or
even lead to chronic epilepsy(13). For example, patients with (nonfebrile) acute
symptomatic (provoked) SE carry a higher risk of subsequent unprovoked seizures
over patients who experienced brief acute symptomatic seizures(14). The risk of an
unprovoked seizure is 3.3 fold higher (41%) after CSE than after a single brief
seizure (13%). Although, this does not necessarily imply that CSE causes epilepsy
because a prolonged seizure may be an indication of considerable brain injury
already present at the time of the initial seizure. This causal relationship holds true in
animal models, for instance, one episode of chemically-induced SE can cause
epilepsy but terminating SE at 30 minutes using anti-convulsant drugs prevents the
development of spontaneous recurrent seizures (SRS)(15). This relationship also
exists in animal models of febrile seizures(16). Currently, prospective cohort studies
such as the North London Convulsive Status Epilepticus in Childhood Surveillance
Study (NLSTEPSS)(17) and the Consequences of Prolonged Febrile Seizures in
Childhood (FEBSTAT) study(18) aim to determine the relationship between
childhood status epilepticus, acute hippocampal injury and the later development of
mesial temporal sclerosis, TLE and cognitive impairment.
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Children with (both febrile and nonfebrile) CSE have been found to perform worse
than controls on neurodevelopmental measures(19). It is not known the extent to
which the seizure causes neuronal injury and the reorganisation of neuronal networks
or whether the factors that predispose children to CSE also are responsible for
cognitive impairment. Cognitive impairment could be considered to be the most
common disability associated with epilepsy(20). In cases of TLE where seizures are
not fully controlled (approximately 30% of patients(21)), cognitive decline is
particularly severe(22). Anti-epileptic drugs (AEDs) that are used to control seizures
are also likely to lead to cognitive and behavioural deficits(23). There is therefore a
need for experimental epilepsy research directed at understanding the processes
behind the development of epilepsy and its comorbidities.
1.5 Animal Models of Epilepsy
The necessity for animal models in epilepsy research cannot be disputed. Only
through animal experimentation is it possible to elucidate the biological mechanisms
behind seizures, epileptogenesis and cognitive dysfunction. Additionally, controlled
experiments enable studies to be performed in animal models with the same
aetiology without the confounding effects of anti-epileptic drugs. Experimental
models have been used in the past for the discovery of new anti-epileptic drugs(24)
and are now being used as an experimental platform for identifying new anti-
epileptogenic drugs that could be used to reduce or prevent the development of SRS.
This topic will be discussed in more detail in section 1.8.
Animal Models of chronic epilepsy (i.e. animals that exhibit unprovoked seizures),
can typically be divided into those which are models of acquired epilepsy and those
which are genetic epilepsies. Only models of acquired epilepsy will be discussed
here. Models of acquired epilepsy can be divided into main two groups: electrically-
induced or chemically-induced epilepsy. SRS can also be induced through the use of
hyperthermia in immature rodents(25) or fluid percussion injury(26). However, these
models have not been as widely studied, possibly because they are not as severe as
the other models in that only a small subset of the affected rats go on to develop
epilepsy. Arguably, these models are more akin to the human situation than the
models based on chemical or electrical stimulation. Nevertheless, all of these models
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can reproduce to some extent the pathophysiological alterations that are present in
patients with acquired epilepsy.
In the models discussed here (with the exception of kindling), spontaneous recurrent
seizures start to develop after self-sustaining status epilepticus (SSSE). There appears
to be a (seizure-free) asymptomatic latency period of several weeks before the onset
of epilepsy, which will be discussed further in section 1.6. The chemoconvulsant
models of epilepsy are those in which chemicals are used to induce status epilepticus.
Chemicals that act on excitatory glutamatergic or cholinergic receptors are either
administered focally (to the brain) or systemically, which subsequently leads to the
induction of SE. One of the main problems with systemic models is the high
mortality rate. In order to reduce mortality, seizures are typically interrupted by using
diazepam 60-120 min after the induction of SE(24). Systemic chemoconvulsant
models are more variable than focal models and have the obvious disadvantage that
large quantities of chemicals introduced into the blood supply have many systemic
effects which may introduce confounding factors. These need to be taken into
consideration in the design of experiments. A major advantage of systemic models is
that they are less labour intensive than focal models. The following three sections
will focus on the systemic chemoconvulsant models and will be followed by a brief
consideration of the electrical models.
1.5.1 Pilocarpine
Pilocarpine is an agonist for muscarinic acetylcholine receptors and is currently one
of the most widely used models of chronic epilepsy. Large doses (300-400 mg/kg of
body weight) of pilocarpine induce electrographic activity in cortical and limbic
regions with concomitant behavioural manifestations which include akinesia and
facial automatisms and the progression to self-sustaining SE. There is known to be a
strong positive correlation between age and mortality in the pilocarpine model of
SE(27), which to some extent emulates the human condition(28). In both animal
models and humans, the developing brain is more susceptible to seizures but much
more resistant to neuronal injury(29). Practically, this means that young adult rats are
most often used to study the effects of SE on brain injury. SSSE primarily causes
injury to the piriform and entorhinal cortices, amygdala, CA1 and CA3 subregions of
the hippocampus as well as to the hypothalamus and subregions of the thalamus(30).
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1.5.2 Lithium-Pilocarpine
Pre-treatment with lithium, within 24 h prior to pilocarpine administration,
significantly reduces the dosage needed to induce status epilepticus in rats by
approximately ten-fold. The lithium-pilocarpine model is very similar in most
aspects to the pilocarpine model. For example, there is a similar pattern of
electrographic activity and neuronal damage(31). Pre-treating rats with lithium
generally results in a higher proportion of animals exhibiting SE, coupled with a
lower mortality rate(32). The underlying mechanisms by which lithium exerts its
effects are largely unknown. Curiously, the situation is different for mice as lithium
does not appear to reduce the dose of pilocarpine required to induce SE(33). Given
that both chemicals also have wide-ranging peripheral effects(34), the mouse
pilocarpine, rat pilocarpine and rat lithium-pilocarpine models should not be
considered as one and the same.
1.5.3 Kainate
Kainic acid (KA) is an agonist for the kainate or KA subtype of glutamate receptor,
which is present at its highest concentrations in the CA3 subregion of the
hippocampus(35). It is widely used in animal models of SE as KA causes
epileptiform activity in the hippocampus as well as a pattern of cell loss which
mimics TLE. In 1987 there was an outbreak of illness in which domoic acid, which is
structurally similar to KA was ingested via contaminated seafood(36). Several of
these patients experienced temporal lobe seizures. Another patient developed
complex partial status epilepticus after domoic acid intoxication and was seizure-free
until one year later when he developed complex partial seizures accompanied by
severe bilateral hippocampal atrophy(37). This event parallels the kainate model of
epilepsy and therefore provides support for its use as a model of the human condition.
1.5.4 Electroconvulsant
Stimulation of the amygdala, hippocampus, entorhinal or piriform cortices using
implanted electrodes can lead to self-sustaining status epilepticus. Similar to the
chemoconvulsant models, seizure severity gradually increases from stage 3 to 5 on
the Racine scale (section 1.5.6). Electrically induced SE leads to bilateral injury to
the limbic regions, thalamus and neocortex(38).
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1.5.5 Kindling
Kindling is unique in that chronic epilepsy is not caused by a single precipitating
event but rather repeated application of (subthreshold) electrical stimuli to the limbic
regions of the brain. These short occurrences of synchronous neuronal firing lead to a
gradual increase in seizure susceptibility over time which is accompanied by
progressive neuronal loss in the CA1 and CA3 subregions of the hippocampus and
hilus of the dentate gyrus(39). It is currently unknown whether kindling can occur in
humans as there is no direct human correlate(11).
1.5.6 Behavioural assessment of seizure severity
Without implantation of electroencephalography (EEG) electrodes, seizure severity
in rodents can be gauged using behavioural scoring. The accepted method of scoring
limbic seizures is the Racine scale(40), which was originally based on electrical
stimulation of the amygdala. The Racine scale consists of 5 stages: (1) Mouth and
facial automatisms, (2) head nodding, (3) unilateral/bilateral forelimb clonus, (4)
forelimb clonus with rearing, (5) rearing and falling. Stages 1 and 2 are sometimes
considered to be partial (or non-convulsant) seizures and 3-5 as generalised(41). The
onset of self-sustaining status epilepticus is often defined as stage 3 on the Racine
scale(42-44) as this is the point at which the seizure becomes generalised and
unmistakeably manifests as forelimb clonus.
1.6 Epileptogenesis
Epileptogenesis typically refers to the process by which a normal brain becomes
epileptic. As noted in section 1.2, in humans, there is an asymptomatic ‘latent period’,
between brain injury and the development of epilepsy. Animal models suggest that
epileptogenesis might be a continuous process and therefore the term ‘latent period’
could be misleading as seizure probability following a precipitating insult appears to
be a continuous function of time rather than a step function(45). For this reason it has
been argued that the term epileptogenesis is poorly defined as it could also include
the possible progression of epilepsy i.e. worsening of seizure frequency(46). The
possible existence of a latent period implies that slowly developing secondary
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processes are responsible for epileptogenesis and also that there exists an extended
therapeutic window during which anti-epileptogenic strategies can be tested(47).
1.7 Processes involved in Brain Injury and Epileptogenesis
The processes involved in epileptogenesis are currently poorly understood. Studies
that have attempted to identify differences between epileptic and control subjects
have identified a large variety of differences. It is not yet known which
pathophysiological alterations are the important contributors in epileptogenesis.
Glutamate excitotoxicity is widely accepted to be the primary underlying mechanism
behind acute seizure-induced brain injury(48), yet it is not capable of explaining the
slow progression of brain injury or the processes involved in epileptogenesis. The
following sections will highlight the key research on the pathophysiological
alterations that occur following status epilepticus.
1.7.1 Glutamate Excitotoxicity and Ischemia
Excitotoxicity is a common mechanism for neuronal injury across many pathological
conditions e.g. status epilepticus, ischemia, traumatic brain injury, alcohol
withdrawal etc. It occurs in situations where there is an excessive concentration of
the excitatory amino acid glutamate. Glutamate acts on NMDA (N-methyl-D-
aspartate) receptors, where it causes an influx of calcium ions. Excessive
concentrations of Ca2+, directly leads to activation of different enzymes such as
protein kinase C, phospholipase A and nitric oxide synthase(49). These enzymes, if
overactivated, generate a number of neurotoxic compounds and free radicals which
can then rapidly lead to cell death via a positive feedback mechanism(50). Although
excitotoxicity is the primary mechanism underlying seizure-induced brain injury, as
SE progresses, lactic acidosis may cause the blood pressure to fall and an insufficient
blood supply may result in ischemia(50, 51) i.e. a shortage in oxygen and glucose.
Evidence from chemoconvulsant models indicates that both excitotoxic and ischemic
mechanisms contribute to brain injury(52, 53) but these models may involve longer
and more severe seizures than typical cases of SE in humans(54).
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1.7.2 Neuronal Loss
Epileptogenic insults are usually associated with cell death. The extent to which this
contributes to a lowering of seizure thresholds or ictogenesis (seizure generation) is
not known. It has been argued that cell death is not necessary for epileptogenesis as it
often does not appear to be detectable in the febrile seizures model(55). In epilepsy
patients as well as animal models, hippocampal sclerosis is normally associated with
the loss of CA1 and CA3 pyramidal cells, hilar mossy cells and hilar peptide-
containing interneurons(56). The selective damage to the CA1 and CA3 subregions
of the hippocampus reflects both the intrinsic circuitry(57) as well as the distribution
of glutamate receptors(58).
Mossy cells in the dentate gyrus form a positive feedback circuit with dentate granule
cells, and for this reason they are thought to be selectively vulnerable to
excitotoxicity during seizures. There are three hypotheses concerning their possible
role in epilepsy(59). The first of these is that loss of mossy cells leads to mossy fibre
sprouting, which will be discussed in the following section. The second is the
‘dormant basket cell’ hypothesis which attempts to explain hyperexcitability in the
hippocampus as the result of loss in mossy cells that synapse with inhibitory basket
cells in the dentate gyrus(60). This particular hypothesis was generated by the need
to explain the observation of decreased inhibition in light of the concomitant
preservation of inhibitory gamma-aminobutyric acid (GABA) containing
neurons(61). At the current time, the plausibility and experimental evidence for this
hypothesis is a matter of debate(62). The third hypothesis is that surviving mossy
cells undergo persistent changes that lead to hyperexcitability.
1.7.3 Progression of Brain Injury
Longitudinal MRI studies in rodents have confirmed that cell loss continues to occur
during the weeks and months that follow SE(44, 63). These changes have been
observed up to 2 months after the initial seizure(64). Crucially, neuronal
degeneration appears to be associated with the initial brain injury and not with the
ensuing seizures. These findings have not been confirmed in humans. Scott et al.
observed increased hippocampal volume asymmetry in children imaged firstly
between 48 h and 5 days of a prolonged febrile convulsion and who had a follow-up
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scan between 4 and 8 months. This indicates a possible causal link between SE and
HS in humans(65), but there is also the possibility that pre-existing asymmetry might
have been obscured by the hippocampal oedema associated with the seizure.
1.7.4 Mossy Fibre sprouting
Mossy Fibre sprouting (MFS) refers to the situation in which axons of dentate
granule cells (mossy fibres) grow into the inner third of the molecular layer of the
dentate gyrus. MFS has been extensively studied and there is much debate about
whether this phenomenon contributes to hyperexcitability through the formation of
aberrant excitatory networks. Arguments against this hypothesis arise from studies
that have shown that cycloheximide can be used to reduce MFS without having any
effect on spontaneous seizures(66, 67).
1.7.5 Inflammation and Blood-brain Barrier Permeability
Epileptogenic insults (e.g. TBI, stroke, status epilepticus etc.) are well known to lead
to microglial activation and recruitment of leukocytes. Furthermore, resected tissue
from temporal lobe epilepsy patients displays elevated levels of several inflammatory
markers(68-70). It is currently unknown whether these observations are merely an
epiphenomenon or whether they play a role in the etiopathogenesis of seizures or
epilepsy. There is emerging evidence to suggest the latter is true and sections 1.8.5-
1.8.8 will discuss experimental studies that have used pharmacological modulation of
inflammation in attempts to disrupt inflammatory processes following SE. The rest
of this section will address the hypothesised mechanisms that link inflammation with
network hyperexcitability and brain injury.
The pro-inflammatory cytokine, Interleukin-1 beta (Il-1β) is thought to enhance 
ictogenesis and seizure propagation. Il-1β inhibits GABA receptor function in 
cultured hippocampal neurons(71, 72). It also enhances NMDA receptor mediated
transmission by both inhibiting outward currents(73) and by enhancing calcium
influx(74). Together, both of these mechanisms will serve to increase excitability of
the hippocampus. In vivo application of lipopolysaccharide (a toll-like receptor 4
agonist) to the cortex can result in epileptiform discharges(75), which can be blocked
by pre-application of an interleukin-1 receptor antagonist. This demonstrates that Il-
1β can induce ictogenesis in vivo and also that other inflammatory cytokines which
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act on toll-like receptor 4 e.g. high mobility group box protein 1 (HMGB1), will
enhance hyperexcitability via Il-1β dependent mechanisms. Seizure activity directly 
leads to HMGB1 release(69) as well as to the release of Il-1β(76, 77). These 
inflammatory cytokines will directly lead to recruitment of peripheral immune cells
and increases in blood-brain barrier (BBB) permeability(78).
Enhanced blood-brain barrier (BBB) permeability has been observed in epilepsy
patients that have recently undergone seizures(79) or status epilepticus(80). Van
Vliet et al.(80) identified dramatic alterations in BBB permeability that present
following electrically induced SE. This pivotal study revealed that seizure frequency
correlates with BBB permeability and that opening of the BBB can increase seizure
frequency. These data signify that BBB permeability might be a key factor in
progression of temporal lobe epilepsy or epileptogenesis in rodents. The mechanisms
for this are thought to occur via the astrocytic uptake of extravasated serum albumin
leading to impaired potassium buffering(81). The mechanisms that are involved in
epileptogenesis can further be elucidated by observing the effects of early
pharmacological manipulation on later brain injury and SRS.
1.8 Therapies for Neuroprotection and the Prevention of Epileptogenesis
According to the International League Against Epilepsy (ILAE), preventing the
development of epilepsy following brain trauma is one of the most relevant and
urgent priorities for researchers(20). Only in the last few years, following the
publication of several high profile research articles, has this been seen to be an
achievable and worthwhile goal. For this reason, there have been several recent
reviews on this subject(82-92). Almost all of these reviews highlight the need for
biomarkers, e.g. biochemical, electrophysiological or imaging measurements that can
be used to track disease progression and monitor the effect of treatments. Imaging
biomarkers, most notably MRI markers have been deemed to be some of the most
promising candidates because they provide exceptional spatial information that other
methods lack. This section will provide an overview of therapies that have been
tested for the purpose of preventing epileptogenesis or neuronal injury and will then
go on to discuss potential biomarkers.
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1.8.1 Neurotrophic Factors
Following cerebral insults, neurotrophic factors (NTFs) are produced in order to
promote stem cell proliferation and differentiation(93). It is possible that expression
of NTFs is insufficient in order to repair the neuronal damage caused by excitotoxic
events. This hypothesis has been tested by using viral vectors to supplement
fibroblast growth factor-2 and brain-derived neurotrophic factor. This combination
therapy reduces neuronal injury as well as the frequency and severity of SRS without
affecting ictogenesis(94).
1.8.2 NMDA Antagonists
Administration of NMDA antagonists following status epilepticus does not confer
protection against the development of epilepsy but does significantly reduce the
degree of neuronal injury in the kainate model(95), presumably due to the
amelioration of excitotoxic effects (section 1.7.1). NMDA antagonists have been
found to have adverse effects in clinical trials for patients with acute stroke(96-98),
indicating that these drugs will not be tested in clinic as a therapy for preventing SE
induced injury.
1.8.3 Anti-Epileptic Drugs
Anti-Epileptic drugs have not proven to be particularly efficacious for the prevention
of epileptogenesis in preclinical studies. Evidence from the clinic also suggests that
AEDs do not have any significant anti-epileptogenic effect(99). Levetiracetam has
been suspected to have anti-epileptogenic properties. Interestingly, it acts in a
mechanism distinct from other AEDs as it binds to synaptic vesicle protein
SV2A(100). In the pilocarpine model, 21 day treatment with levetiracetam had a
dose-dependent effect on hippocampal hyperexcitability in the dentate gyrus as
measured by population spike amplitude(101). This conflicts with a previous study
that found no significant effect in seizure frequency in a kindling model(102).
Carisbamate is an AED that has not yet been approved by the United States Food and
Drug Administration. Compared to diazepam, it might have anti-epileptogenic
properties in the lithium-pilocarpine model(103), but the degree to which this effect
was due to the alleviation of SE severity is unknown.
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1.8.4 Rapamycin
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase
with a wide range of functions including synaptic plasticity(104). Administration of
rapamycin following kainic acid induced SE, dramatically reduces SRS(105). In the
rat pilocarpine model, rapamycin treatment in the chronic epilepsy phase confers
suppression of seizure activity, which begins to return on cessation of treatment(106),
suggesting that rapamycin may suppress ictogenesis. Although its mechanism of
action is largely unknown, administration following SE reduces the biphasic
activation of the mTOR pathway(105) and has been found to reduce MFS in 2
different models of epilepsy(105, 107). Interestingly, it has also been associated with
a reduction in BBB permeability compared to controls(108), therefore it is possible
that its anti-epileptogenic effects might occur via this mechanism. Rapamycin has no
effect on epileptogenesis in the mouse pilocarpine model(109).
1.8.5 Anti-inflammatory therapies
Many studies have shown various anti-inflammatory drugs to be neuroprotective or
anti-epileptogenic following status epilepticus. For this reason and because there are
many already clinically approved compounds, they are the most promising
candidates for translation into clinic. The following sections will review the key
research on this topic.
1.8.6 Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs have wide-ranging effects depending on the
animal model used and schedule of administration after SE. Following electrically
induced SE(110), Holtman et al. observed no effect of SC58236, a selective
cyclooxygenase-2 (COX-2) inhibitor, on cell death or microglial activation in the
hippocampus. In contrast to this study, Parecoxib, another selective COX-2 inhibitor
administered for 18 days following lithium-pilocarpine induced SE was shown to be
neuroprotective but not anti-epileptogenic(111). Celecoxib reduces neuronal injury
and microglia activation when administered one day after lithium-pilocarpine
induced status epilepticus(112). Conditional ablation of COX-2 in forebrain neurons
reduces hippocampal injury in the CA1 subregion of the hippocampus at 4 days post
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pilocarpine induced status epilepticus, however there is some evidence to suggest
that COX-2 is neuroprotective at 24 h following the insult(113).
1.8.7 Corticosteroids
Corticosteroids such as dexamethasone (DEX) act on the glucocorticoid receptor and
are highly effective in reducing BBB permeability. DEX does not readily cross the
BBB(114) and the mechanisms by which these corticosteroids are BBB protective
are numerous. Three known mechanisms involve the induction of annexin I,
induction of mitogen-activated protein kinase phosphatase I and the blocking of
nuclear factor kappa B (NF-κB)(115). The glucocorticoid receptor is expressed 
ubiquitously and in vitro studies suggest that dexamethasone exerts an effect directly
on endothelial cells(116). DEX reduces infarct volume when administered following
cerebral ischemia in rats(117), supporting the view that DEX may also alleviate brain
injury following status epilepticus. Two recent studies have found that
dexamethasone is neuroprotective when administered prior to pilocarpine or lithium-
pilocarpine induced status epilepticus(118, 119). The mechanisms of this are thought
to occur via the alleviation of vasogenic oedema and subsequently less severe status
epilepticus. However, the clinical relevance of these studies is debatable as
administration of dexamethasone preceded the insult.
1.8.8 Other Anti-Inflammatory Therapies
Interleukin-1 beta is an early pro-inflammatory cytokine that is released from
astrocytes following brain injury and which is known to be a key mediator of BBB
permeability(120). VX-765 is a drug that inhibits Interleukin Converting Enzyme
(ICE) and hence IL-1β production. VX-765 interrupts the development of kindling in 
rats, whilst having no effect on seizures in fully kindled rats(121). Combined VX-
765 and interleukin-1 receptor antagonists given shortly after electrically induced SE
confers significant neuroprotection across most affected brain regions(122).
Interestingly, the effect on neuronal injury is much more limited in the lithium-
pilocarpine model and the treatment had no effect on SRS in either model. In the
mouse pilocarpine model, Fabene et al. showed that blocking leukocyte-endothelial
interactions following SE (via administration of α4 integrin specific antibodies), 
reduces the occurrence of SRS(123). This finding was also associated with a
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reduction in BBB permeability in the acute phase after SE. The same study found
elevated numbers of leukocytes in cortical tissue from epilepsy patients compared to
controls highlighting a possible drug target in the human condition.
1.9 Biomarkers of Epileptogenesis and Neuronal Injury
The term biomarker can be defined as: ‘a laboratory measurement that reflects the
activity of a disease process(124).’ Useful biomarkers of epileptogenesis could
include: measurements that enable a definitive prediction of epilepsy development
and also those that enable the assessment of anti-epileptogenic therapies(125).
Animal models will be crucial for the identification of new biomarkers. Roch et al.
used the lithium-pilocarpine model in immature rats to test whether T2 weighted MRI
could predict the development of SRS(126). They found that early (24 h after SE) T2
abnormalities in the piriform cortex predicted the development of epilepsy. Using the
adult rat lithium-pilocarpine model, Choy et al. used principal component analysis to
show that a combination of T2, cerebral blood flow and T1 was predictive of neuronal
injury(44). Another imaging study in the pilocarpine mouse model found that much
later (7 days after SE) alterations in diffusion MRI images in the hippocampus
predicted interictal (between seizure) spike frequency in the chronic epilepsy
phase(63). Finally, a study based on implanted electrodes in the dentate gyrus found
that the time between SE and high-frequency oscillations on EEG predicted the
duration of the latent period between SE and SRS in the focal kainate model(127).
1.10 Summary
This chapter has highlighted the need and interest for therapies that can prevent brain
injury and epileptogenesis following cerebral insults. Several problems persist in this
area, for example most outcomes appear to depend on the animal model used and the
time course of drug administration. Another issue is the current need to identify
biomarkers for epileptogenesis and therapy monitoring. The following chapters will
aim to demonstrate that in vivo magnetic resonance imaging is a powerful tool that
may aid in our understanding of the processes that follow status epilepticus, and that
it can provide a platform for testing new and existing therapies.
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Chapter 2 Magnetic Resonance Imaging
In 1922 Otto Stern and Walther Gerlach demonstrated, in what is now known as the
Stern-Gerlach experiment, that atoms possess quantised angular momentum. Their
experiment involved passing silver atoms from a hot oven through an
inhomogeneous magnetic field. Classical physics would predict that if these silver
atoms possessed a distribution of angular momentum, then they would be deflected
in this inhomogeneous field to produce a distribution in space. What they found was
instead of a distribution in space, the atoms were deflected to either one of two paths.
This illustrates two important points that are necessary for an explanation of nuclear
magnetic resonance or MRI. First, a magnetic moment with intrinsic angular
momentum (such as the nucleus of an atom) precesses in a magnetic field, which is a
classical phenomenon. Second, this experiment illustrated the quantum mechanical
phenomenon of quantisation of angular momentum. This means that the angular
momentum can only have certain values. Based on quantum mechanics, the angular
momentum is only allowed to take on (2I+1) possible values, where I is the nuclear
spin quantum number. For protons, which are the source of signal in MRI, I=1/2,
meaning that there are only 2 allowed values for angular momentum. The component
of the angular momentum projected along the z axis (direction of the field) is given
by mI, can therefore only take on 2 values, mI=±1/2 (‘parallel’ or ‘anti-parallel’ to the
magnetic field). The energy (E) of these states can be found from the Schrödinger
equation:
ூ 1
where γ is the gyromagnetic ratio (the ratio of the magnetic moment to the intrinsic
angular momentum),  is Planck’s constant divided by 2π and B is the applied
magnetic field. The difference in energy (ΔE) between the two states (mI=±1/2)
depends on the applied field B and can easily be found from equation 1 to be equal
to:
2
ΔE is the energy of electromagnetic radiation needed to excite a proton from the mI=-
1/2 state to the mI=+1/2 state. Classically, it is also the frequency (ω) at which the
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magnetic moment ( ࡵ precesses around the magnetic field. According to classical
physics, an external magnetic field exerts a torque ( on a magnetic moment which
is equal to(128):
ࡵ 3
where is the angular momentum. As ࡵ , the change in the magnetic
moment over time is given by(128):
ࡵ
ࡵ 4
and from equation 4, it can be deduced that the change in magnetic moment over
time is perpendicular to the plane defined by and ࡵ, hence there is a precession of
ࡵ around . As already noted, the frequency of precession, or Larmor frequency, is
also equal to the quantum mechanical transition energy from equation 2. The
ratio of the number of nuclei in each energy state ( ௠ ಺) can be estimated from the
Boltzmann factor:
௠ ಺సషభ/మ
௠ ಺సశభ/మ 5
where k is Boltzmann’s constant. This difference in populations can be used to
explain the net magnetic moment in the z direction of an ensemble of nuclei.
If a radiofrequency (RF) pulse is applied perpendicular to the magnetic field at the
frequency ω, this causes nuclei to transition between parallel and anti-parallel states
which alters the populations of the spin states. This can be visualised through the use
of a coordinate system rotating around the z axis at the Larmor frequency.
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Figure 1: Magnetisation in a rotating coordinate system in the spin-echo
and gradient-echo pulse sequences. (a)-(d): gradient echo sequence. (e)-(h):
spin-echo sequence. (a) Initial magnetisation in a magnetic field aligned with
the z axis. (b) Magnetisation following an RF pulse (B1) of flip angle α applied 
parallel to the y axis. (c) Application of a dephasing gradient causes spins to
precess out of phase. (d) Dephased spins are then focussed to form an echo
aligned with the x axis using a readout gradient of opposite polarity. (e) Initial
magnetisation. (f) Following application of a 90º RF pulse (B1). (g) After
prephasing, a 180º pulse is applied, which causes spins to rotate 180º around the
x axis. (h) Focussing is achieved using a readout gradient with the same polarity
as the prephasing pulse.
At equilibrium, the net magnetisation is aligned with the main field (B0) (Figure 1a).
Following the application of a magnetic field (B1) oscillating at the Larmor
frequency, the net magnetisation is rotated towards the xy plane by an angle α 
(Figure 1b). This angle is known as the flip angle (FA) and depends on the strength
and duration of the applied field B1. Following application of the RF pulse, the
magnetic moments of a small proportion of the nuclei in the system begin to precess
around the B0 field in-phase, which is what leads to the presence of net magnetisation
in the xy plane.
The decay back to the equilibrium state is what is usually measured in the nuclear
magnetic resonance (NMR) experiment and the measured signal is called the free-
induction decay. The decay process of the z component of magnetisation ( ௭ is
known as spin-lattice relaxation. ௭ decays as described by equation 6 and the decay
constant is denoted by T1 (Figure 2a). In the xy plane, it is known as spin-spin
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relaxation and the decay constant is T2 or T2* (Figure 2b). T2 is used if an RF pulse is
used for refocusing of the decaying magnetisation (as is the case in the spin-echo
experiment discussed in the next section), and T2* is used if this is not the case. The
decay of magnetisation in the xy plane ( ௫௬) is described by equation 7. We have not
yet considered how images can be formed in MRI and so this will be the topic of the
next section.
௭ ௭ ଵ 6
௫௬ ௫௬ ଶ 7
Figure 2: Exponential decay of net magnetisation back to equilibrium
following application of an RF pulse. (a) Longitudinal (z) component of
magnetisation. (b) Transverse magnetisation (magnetisation projected onto the
xy plane).
2.1 Basic Imaging Sequences
Spatial information is encoded in the MRI signal through the use of temporary
magnetic field gradients and RF pulses. Firstly, (in a two-dimensional (2D) multi-
slice sequence) the signal from one slice of the imaging volume can be localised by
selective excitation of this region. This is achieved by simultaneously applying a
temporary magnetic field (slice-select gradient-Gss) and a RF excitation pulse with
the correct frequency and bandwidth (Figure 3a,b). Within this plane, spatial
information is encoded in one direction using a temporary gradient applied during
the acquisition (readout gradient-Gro) in a technique known as frequency encoding.
M
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a
36
The localisation in the final direction is achieved using a different temporary gradient
(phase-encoding gradient-Gpe) orthogonal to the frequency encoding gradient. This
leads to a different phase-shifted signal at each location and hence this is known as
phase-encoding. The strength of the phase encoding gradient is systematically altered
in order that each location experiences a range of phase shifts. In the plane defined
by the frequency and phase-encoding axes, the acquired signal is organised in
frequency space (k-space), with the frequency and phase-encoding directions
arranged orthogonally. k-space can be Fourier transformed to generate the MRI
image.
Two most fundamental imaging pulse sequences in MRI are the gradient-echo
sequence and the spin-echo sequence. In the gradient-echo sequence, firstly an RF
pulse is applied with a flip angle α (Figure 3a) and the subsequent acquisition is 
performed at a time known as the echo time (TE) after the initial excitation pulse.
Prior to the readout at time TE, a dephasing (or prephasing) gradient is applied. This
has the effect of dispersing the spins (Figure 1c). Applying a readout gradient with
reversed polarity enables the creation of a measureable echo at time=TE (Figure 1d).
The spin-echo sequence consists of excitation with a 90º excitation pulse, followed
by application of a prephasing readout gradient (Figure 3b). A 180º pulse is then
applied which has the effect of rotating the spins 180º about the x axis (Figure 1g).
This 180º pulse has the effect of reversing phase accumulation due to off resonance
effects, e.g. slight variations in the static B0 magnetic field. Finally, an echo is
generated by applying a readout gradient with the same polarity (Figure 1h).
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Figure 3: Basic MRI pulse sequences. (a) Gradient echo. (b) Spin echo.
RF=radio frequency, Gro=readout gradient, Mxy=transverse magnetisation,
Gpe=phase encoding gradient, Gss =slice select gradient.
2.2 T1 and T2 Weighted Imaging
The signal intensity (S) in a spin-echo experiment is given by:
ଵ ଶ 8
where k is a hardware dependent parameter and is the spin density. If the TR is
long (compared to T1) and the TE is long (compared to T2), then S depends strongly
on the T2 of the tissue and the sequence is then said to be ‘T2 weighted’. If the TR is
short and TE is short, then S is more strongly dependent on the T1 of the tissue.
Endogenous tissue contrast in MRI is derived from inherent differences in the decay
constants T1, T2 and T2* for different tissues. This illustrates how the pulse sequence
parameters can be tuned to afford optimum contrast between different tissues. The
signal intensity of a gradient-echo experiment will be discussed in the following
chapter. More specialised pulse sequences can generate contrast that is sensitive to
water diffusion, magnetisation transfer (between protons in macromolecules and free
water) or tissue perfusion.
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2.3 T2 Relaxometry
The measurement of the transverse magnetisation relaxation time constant (T2)
provides a quantitative and more objective measure than T2 weighted imaging.
Reasonable estimates of T2 can be found using multi-echo spin-echo sequences at
long repetition times (Figure 4). Multi-echo sequences involve using multiple
refocussing pulses to sample the transverse magnetisation at different points along
the decay curve (Figure 2b, equation 7) and then fitting a monoexponential decay
function to the data.
Figure 4: Multi-echo spin-echo pulse sequence for quantitative T2
measurements. NE = number of echoes, TEn = echo time of the nth echo.
2.4 Fast Spin-Echo
Standard spin-echo sequences have generally been superseded by more time-efficient
sequences. In experimental studies, fast spin-echo (FSE) sequences, (otherwise
known as rapid acquisition with refocused echoes (RARE)) are much more
frequently used. This sequence is very similar to the multi-echo sequence shown in
Figure 4, the only difference being that in multi-echo sequences, the same line of k-
space is acquired, whereas in FSE, subsequent echoes are phase encoded in order to
fill k-space (Figure 5). This leads to an improvement in acquisition time. The
improvement factor is equal to the number of acquired echoes, otherwise known as
the echo train length (ETL). The effective echo time (TEeff) is the time after the
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excitation pulse at which the centre of k-space (which contains the most signal) is
traversed.
Figure 5: Fast spin-echo pulse sequence. ETL = echo train length, TEn = echo
time of the nth echo.
2.5 Echo-Planar Imaging
Ultrafast MRI imaging can be achieved using echo-planar imaging (EPI). In single-
shot EPI, an entire stack of images is acquired within a single TR. This sequence is
typically used in functional MRI for observing brain activity as it affords time
resolution that is on the order of seconds, which is fast enough to observe changes in
blood flow that are associated with neuronal activity (section 7.3). In the EPI
sequence (Figure 6), transverse magnetisation is continually rephased by the readout
gradient and the phase-encoding gradient is applied prior to each echo. In single-shot
EPI, this means the entirety of k-space can be traversed within one excitation.
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2.6 2D vs. 3D sequences
In 2D multi-slice pulse sequences, data from several slices are acquired during one
TR. This is achieved by exciting one slice at a time using a slice selective gradient
and a shaped RF pulse. In three-dimensional (3D) sequences, an entire set of slices (a
slab) is excited simultaneously. Position is then encoded in the slice direction by
introducing another phase encoding direction. 3D acquisitions are advantageous in
that they are able to acquire much thinner slices than is possible with multi-slice
sequences. 3D acquisitions can also be more efficient in terms of signal-to-noise ratio
(SNR) per unit time(129), however the total acquisition time tends to be much longer.
For 3D pulse sequences with rectilinear sampling, the total acquisition time ( ௧௢௧ଷ஽)
is given by equation 9:
௧௢௧ଷ஽ ௣௘ ௣௘ଶ 9
where ௣௘ is the number of phase encoding steps, ௣௘ଶ is the number of phase
encoding steps in the second phase encoding direction and is the number of
excitations (number of averages). The total acquisition time for multi-slice sequences
( ௧௢௧ଶ஽ is given by:
௧௢௧ଶ஽ ௣௘ 10
Figure 6: Gradient-echo echo-planar imaging pulse sequence.
41
This means that in general, the TR needs to be shorter in 3D sequences compared
with multi-slice sequences in order for the acquisition time to be of a practical length.
2.7 Summary
This chapter has introduced many basic concepts in MRI, such as imaging pulse
sequences and sequence parameters that will be needed for a comprehensive
understanding of the work presented in the subsequent chapters.
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Chapter 3 Development of Experimental Protocols and Image
Analysis Methods
The aim of this project is to develop MRI imaging methods that can be used to non-
invasively monitor the effects of status epilepticus. This thesis focusses on 4
techniques: molecular imaging using iron oxide particles, quantitative measurements
of T2, volumetric MRI and functional MRI. The motive for using iron oxide for
molecular imaging stems from several recent publications demonstrating its
enormous potential for monitoring expression of inflammatory markers in vivo.
Further discussion on this topic is included in the next chapter. The reasons for using
T2 relaxometry and volumetric imaging is that these are generally accepted measures
of oedema and hippocampal sclerosis(130).
The first part of this chapter will focus on the design of experimental protocols,
starting with the development of a protocol for the lithium-pilocarpine model of
epilepsy. Following from this, the use of iron oxide contrast agents will be discussed.
The final topic of the chapter will be the design of imaging protocols and image
analysis methods.
In all of the work presented in this chapter as well as Chapters 4, 5 and 6 (part I and
II), an Agilent Technologies 9.4T MRI scanner was used, which is located at the
Centre for Advanced Biomedical Imaging at UCL. In Chapter 6 part III and Chapter
7, a 7T Bruker PharmaScan system was used, which is located at the Institute of
Development, Aging and Cancer at Tohoku University. Unless otherwise stated, all
chemicals were obtained from Sigma Aldrich, UK.
3.1 Animal Model of Epilepsy
In this project, I have opted to use the rat lithium-pilocarpine model to study the
effects of status epilepticus on the brain. The reasons for this are firstly because the
lithium-pilocarpine model is one of the most studied models of status epilepticus and
secondly because previous studies in the department have used this model and
therefore there is available expertise. The lithium-pilocarpine model (section 1.5.2)
and the kainate (section 1.5.3) model are similar in many respects. Both have a
mortality rate of around 20-40% and result in chronic epilepsy after a period of
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weeks or months(131). It should be noted that the chemoconvulsant models may not
be the most appropriate models of epileptogenesis in humans. Models in which only
small subgroups of rodents develop epilepsy are much more akin to the human
condition, but are more impractical for discovering biomarkers for epilepsy.
Preliminary experiments using the lithium-pilocarpine model were conducted using
adult male Sprague-Dawley rats (weighing between 170-200 g, supplied by Charles
River UK Ltd, Margate UK) and the protocol outlined below:
- Intraperitoneal administration of lithium chloride (3 mEq/kg), approximately
12 h prior to pilocarpine.
- Intraperitoneal injection of methylscopolamine nitrate (5 mg/kg) 20 min prior
to pilocarpine. Methylscopolamine does not cross the BBB and is used to
reduce the peripheral effects of pilocarpine.
- Intraperitoneal injection of pilocarpine hydrochloride (30 mg/kg).
- Behavioural assessment of seizure severity using the Racine scale (section
1.5.6).
- Intraperitoneal injection of diazepam (10 mg/kg, Hameln Pharmaceuticals,
Gloucester) after 90 min of SE to terminate the seizure.
Using the standard protocol outlined above, it was found that only 2 of 3 rats
underwent status epilepticus. Chaudhary et al. reported that shortening the time
between lithium and pilocarpine administration has the effect of increasing the
number of rats that undergo SE(132). By adopting a new modified protocol in which
lithium chloride was administered 2 h prior to pilocarpine, it was found that 12 out of
12 (100%) of rats progressed to SE. 1 animal in this experiment died during SE,
therefore the mortality rate (8%) in this pilot study was low compared to the typical
rates reported in the literature(31).
This section has focussed on the development of a protocol for the lithium-
pilocarpine model. The next section will focus on how iron oxide can be used as a
contrast agent for MRI and the following 2 sections will address imaging protocols
that will be used to investigate this animal model.
44
3.2 Superparamagnetic Iron Oxide Nanoparticles as MRI Contrast Agents
Iron oxide is normally a mixture of magnetite (Fe3O4) and maghemite (Fe2O3). These
compounds are usually ferrimagnetic meaning that if placed within a magnetic field
they become magnetised into permanent magnets and exhibit a net magnetisation
below what is known as the Curie temperature. Above this temperature, these
materials become paramagnetic which refers to the situation where the magnetisation
is a linear function of the applied magnetic field and removed from the field, all
residual magnetisation is lost. Iron oxide particles of a single magnetic domain,
existing below a certain diameter (normally several hundred nanometres) act as
paramagnets. They are said to exhibit ‘superparamagnetism’ as they behave as
paramagnets with a large magnetic moment.
Compounds which are ferrimagnetic will be drawn together due to the attractive
force between two magnetic dipoles, leading to particle aggregation.
Superparamagnetism is an extremely useful property for biomedical applications, the
reason being that outside of a magnetic field, superparamagnetic particles retain no
net magnetisation, therefore magnetic interactions are not a significant driving force
for the formation of aggregates. However, when placed within a field, particles
exhibit a large magnetic moment which is useful for MRI applications as they cause
a magnetic field distortion which is detectable using MRI. Furthermore, iron oxide is
non-toxic and biodegradable, rendering it safe for biomedical application. The
magnetic field offset (f) surrounding a dipole depends on the angle to the main field
and the radial distance to the dipole (r) (equation 11)(133):
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where γ is the gyromagnetic ratio and is the angle between the position vector and
the external magnetic field. Iron oxide particles therefore cause alterations in the
applied magnetic field which falls off with the cube of the distance from the particle.
3.3 Imaging of Iron Oxide Particles
Magnetic field distortions caused by magnetic nanoparticles can be visualised on
MRI images as local variations in the magnetic field leads to faster dephasing of
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magnetisation. Gradient-echo is one of the most sensitive pulse sequences for iron
oxide detection as it is more sensitive to local field distortions than spin-echo
sequences with refocusing RF pulses (section 2.1).
The signal intensity in a gradient-echo experiment is given by:
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where M0 is the initial transverse magnetisation. From equation 12 it can be shown
that the flip angle (α) which maximises the signal intensity at a given TR and T1 is
given by the Ernst angle ா (Figure 7):
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Figure 7: Repetition time vs. optimum flip angle (Ernst angle) for spoiled
gradient-echo imaging.T1 = 1 s
For the detection of iron oxide, we wish to maximise the contrast between two
regions rather than the overall signal intensity. Iron oxide causes a decrease in T2*
and T1, but for larger particles e.g. micron-sized particles, T2* effects dominate and
therefore T1 effects can generally be ignored. The contrast-to-noise ratio (CNR) can
be written as the signal difference between two regions divided by their mean noise.
Let these two regions be denoted as A and B, where region A contains the contrast
agent (CA) and region B which does not(134). The CNR is then equal to:
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where k is the proton density and N is the mean image noise. If the T1 in both regions
is assumed to be the same, the T1 terms can be factored outside the brackets. The
term outside the brackets is equal to the SNR and can be maximised using the Ernst
angle (equation 13). The term inside the brackets is the difference between 2
exponential decay functions and depends on the TE of the sequence. Based on this
reasoning, the CNR increases with TE until it reaches a maximum and then tails off.
The above model does not provide a satisfactory model of any real in vivo situation,
in which there exists a small number of iron oxide particles unequally distributed
within a voxel. Moreover, particles which are close enough to each other in
proximity will tend to form aggregates further highlighting the difficulties involved
with estimating iron concentrations. Nevertheless, work reported in the
literature(135) suggests that using iron oxide particles as MRI contrast agents may be
extremely sensitive as a molecular imaging approach. The next chapter will attempt
to demonstrate this sensitivity in vivo with a comparison to nuclear imaging whilst
the remainder of this chapter will focus on the more routinely performed imaging
techniques, relaxometry and volumetric imaging.
3.4 Relaxometry Protocol and Data Analysis
T2 weighted imaging (section 2.1) is used extensively in clinic for detection of both
oedema and hippocampal sclerosis. Acute increases in T2 following cerebral insults
such as hypoxia-ischemia or status epilepticus are thought to indicate cytotoxic
oedema or vasogenic oedema(136). Cytotoxic oedema in the brain refers to the
swelling of neurons and astrocytes due to water diffusion from the extra-cellular
compartment to within cells. It is generally considered to be caused by energy failure
and the failure of the sodium-potassium pump, which in turn can be caused by
glutamate excitotoxicity. Cytotoxic oedema is responsible for early T2 increases
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following excitotoxic insults, whereas later (between 12-24 h) increases are thought
to be primarily caused by vasogenic oedema(137-139). Vasogenic oedema describes
the process by which the water content of parenchymal tissue increases due to an
impaired BBB. T2 changes have been shown to correlate reasonably well with tissue
water content 24 h following hypoxic-ischemic insults, which demonstrates that T2 is
a reliable marker of vasogenic oedema(139). T2 lengthening in the case of oedema is
thought to be caused by a higher ratio of ‘free’ to ‘bound’ water(140). Free water is
known to have a longer T2 than bound or structured water. Reduced magnetisation
exchange between the free and bound water protons is also thought to play a
role(141). However, the fluid that leaks from blood vessels in the case of vasogenic
oedema is protein rich, which further complicates the picture(142).
T2 relaxometry refers to the situation where T2 is estimated by acquiring images at a
range of echo times. Relaxometry can be more sensitive(143) and is likely to be more
comparable between subjects than conventional T2 weighted imaging as signal
intensity can vary between imaging sessions due to a variety of factors. T2
relaxometry conducted on a voxel-wise basis is called T2 mapping. As noted in
section 2.3, this can be carried out within a realistic acquisition time by using a
multi-echo spin-echo sequence.
In this project, the default multi-echo spin-echo sequence on the Agilent MRI
scanner was used. Stimulated echoes are often a problem in sequences that involve
refocusing RF pulses. If the 180º refocusing pulse is non-ideal, this tips some of the
magnetisation into the z direction which can then create a stimulated echo using
another non-ideal pulse. The result of this is that the first echo (which does not
contain a stimulated echo component) has a lower signal intensity than the second
echo which does. The remaining echoes display an approximate monoexponential
decay with an artificially long T2(144). This did not appear to be a significant
problem in the pilot data (Figure 8) therefore no further optimisation of the sequence
was carried out. In brain regions where there was low SNR, the signal decayed to
below the noise level at the later echo times, causing a deviation from
monoexponential decay (Figure 8).
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z
Figure 8: Example of non-monoexponential decay of signal intensity at
later echo times. Echo time vs. log of the mean signal intensity from a region
located in the striatum. Solid line shows a linear least-squares fit to the first 7
data points.
Figure 9: Use of power images for noise correction in T2 Relaxometry.
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Figure 10: Effect on T2 by fitting points from an increasing number of
echo times. Effect of fitting points from 3-7 echo times: for (a)-(e)
respectively. T2=42.22, 43.18, 43.24, 43.29 and 43.43 ms for (a)-(e)
respectively. Error bars represent the standard deviation of values within the
region of interest.
In order to correct for this problem, Miller et al.(145) demonstrated that subtracting
the squared background signal from the square of the magnitude of the image
(otherwise known as the power of the signal) leads to a new noise-corrected image.
The corrected T2 decay constant is then equal to twice the decay constant from the
power images (equation 15). In the case of low SNR in later echoes, this method can
drastically improve the curve fitting and thus T2 estimation as confirmed in Figure 9.
Figure 10 shows that after noise correction, fitting points from later echo times in
which noise is a large component of the total signal, at most can be seen to cause a
negligible lengthening of T2 estimates.
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3.5 Structural Imaging
An in vivo experiment (n=1) was conducted in order to determine suitable MRI
sequence parameters for the structural imaging protocol. As noted in section 2.4,
typically multi-echo sequences tend to be more efficient in terms of SNR per unit
time than the standard spin-echo sequence. Therefore for structural imaging I have
opted to use a fast-spin echo sequence. FSE is used often in structural MRI as it
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offers a significant time advantage over single echo techniques. This SNR
improvement derives from the fact that several lines of k-space are filled within a
single TR. A scan with ETL=4 offers a 4 fold acceleration in acquisition time over a
standard spin-echo sequence. Figure 11a shows a 3D FSE image with ETL=8,
TEeff=41.8 ms and acquisition time=48 min. If the TR is doubled, an ETL of 16 can
be used to produce a sequence with the same acquisition time and at the same time
offer a 64% improvement in SNR (Figure 11b). As a result of this increase in SNR, it
was possible to increase the spatial resolution to have an isotropic voxel-size of 150
µm, whilst retaining sufficient SNR (Figure 11d).
There needs to be a compromise as increasing the ETL means that the lines of k-
space that are filled at later echo times have lower signal, meaning that the edge of k-
space, which encodes higher spatial frequencies, records less signal and results in
blurring of the image. There are methods to alleviate this problem, for instance by
using variable refocusing flip angles, but implementing this is beyond the scope of
this project. A visual comparison of Figure 11a and Figure 11b suggested that this
did not appear to be a significant problem in the pilot data. The default parameters
for the 3D FSE sequence on the Agilent MRI scanner produces images that contained
streaking artifacts (Figure 11a,b) which is likely to have occurred as a result of
unwanted stimulated echoes. Increasing the amplitude of the crusher gradient, (which
nulls transverse magnetisation) was able to remove this artifact as can be seen in
Figure 11c. Gibbs ringing artifacts were also present at the interface between the
brain and the surrounding tissue (Figure 11d). These were alleviated at the expense
of spatial resolution by applying a Tukey filter in k-space to smooth the images
(Figure 11e).
Several datasets were not able to be used due to signal dropout in the posterior
regions of the brain (Figure 12a). This artifact was identified to be due to the
frequency pre-scan incorrectly identifying the excitation frequency offset which in
turn led to a failure to excite the first 100 slices in the imaging volume as shown by
the signal intensity profile in Figure 12b. These datasets were irrecoverable and had
to be discarded. The first part of this chapter has been concerned with the
development of imaging protocols whilst the remainder focusses on deriving
quantitative information from the acquired images.
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segmentation is essential. Segmentation problems are subjective by nature and
therefore in most situations the ground-truth can be considered to be manual
segmentation. Manual segmentation is a hugely laborious task, particularly when
dealing with neuroimaging data, in which we are interested in several brain regions
or even several hundred brain regions, therefore automated methods are highly
desirable. There are numerous approaches to solving this problem that are applicable
in different situations but one of the most important issues is how much prior
information is used and how it can be incorporated.
Atlas-based segmentations are incredibly useful in neuroimaging and rely on
registering (transforming) an atlas (i.e. a pre-segmented image) to the target image
(image to be segmented) or vice versa. Recently, multi-atlas approaches have been
found to be superior to single-atlas approaches and are starting to be applied to
neuroimaging datasets(146).
3.7 Single-Atlas Based Segmentation
Manual region drawing can be incredibly laborious work, for example a typical study
in with 3 time-points, 40 subjects and 10 regions of interest (ROIs) per dataset would
require 1200 regions to be drawn, which is clearly undesirable and expensive if
trained operators are recruited to perform this task. In order to reduce the labour
intensiveness of manual region drawing, automated methods can be applied. One of
the simplest automated approaches involves registration to a parcellated MRI
template (atlas). Prior to the registration, it is often necessary to perform image
preprocessing. Three preprocessing steps that can dramatically improve the quality of
the image registration are: inhomogeneity correction, intensity normalisation and
brain masking. These will be discussed in turn in the following sections.
3.8 Inhomogeneity Correction
Image inhomogeneity or bias fields are smooth variations in signal intensity across
images that occur as a result of imaging hardware. It occurs primarily due to the
spatially varying sensitivity of receiver coils but can also be caused by non-uniform
excitation. Correcting for these inhomogeneities is normally necessary prior to
coregistration. By far the most popular algorithm used for bias field correction is the
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intensity normalisation is sometimes desirable. The simplest type of normalisation
can be achieved by linearly scaling intensity values to a new intensity range using
equation 17:
ே 17
where IN is the new image intensity, I is the original intensity, Min and Max are the
original minimum and maximum intensities of the image respectively and newMin
and newMax are the desired minimum and maximum intensities respectively. Whilst
a simple method such as the one used above, can ensure that the range of intensities
is the same for all images, more complicated methods based on histogram landmarks
can offer significant gains in similarity between intensity histograms.
Small numbers of voxels with vastly different intensity values are common in MR
datasets. For instance, DC offset artifacts or blood vessels often present as
hyperintensities and will skew analyses of histogram parameters such as the
maximum, mean and standard deviation (SD). It can therefore be appropriate to
remove such outliers before performing intensity scaling. The values that fall within
this range can be said to be within the intensity range of interest.
The method that we utilise here for intensity normalisation is an implementation of
the work described by Nyúl et al.(152), which is based on firstly, linearly scaling all
intensities between the 1st and 99th percentile to a standard intensity range. After this,
multiple standard landmarks are then calculated. In this case, the deciles of the
intensity values are averaged over all of the training datasets in order to find these
standard landmarks. Once these are found, the landmarks of each individual MRI
dataset are linearly mapped to the standard landmarks using equation 17. This
algorithm was implemented in MATLAB (MathWorks, Natick, MA) by Nicholas
Powell from the Centre for Advanced Biomedical Imaging at UCL.
3.10 Brain Masking and Measurement of Total Brain Volume
Brain masking or brain extraction is essential for many MRI analyses in small animal
studies because it improves image registration and also because segmentation of the
brain is needed as a measurement of the total brain volume. There has been much
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attention focussed on the problem of brain extraction of human MRI datasets and as
a consequence there is much freely available software for this purpose. However, the
problem of rodent brain extraction has relatively been neglected and software that is
designed for human brain extraction performs poorly on rodent brain datasets.
Recently, three different methods have been proposed for rodent brain extraction
based on deformable surfaces(153), constraint level sets(154) and 2D and 3D pulse-
coupled neural networks(155-157).
One of the most successful and widely applied approaches is the Brain Extraction
Tool (BET)(158) in FSL (www.fmrib.ox.ac.uk/fsl), which is based on deformable
models. In most situations, BET performs adequately, however in this project it was
found that an atlas-based approach, which can incorporate a large amount of prior
information, was vastly superior to techniques primarily based on morphology and
signal intensities. There are two disadvantages to using an atlas-based approach. First,
it is less generalizable, therefore will not be as accurate on datasets acquired with
different imaging parameters or on subjects with brain morphology that is too
dissimilar to that of the atlases and second because it requires the generation of high
quality atlases (i.e. a number of datasets that have been segmented to a high degree
of accuracy). As generalisation is not a major problem in this work (i.e. we are using
the same imaging parameters and adult rodents of the same species and a similar age),
an atlas based approach is ideal as it will be highly insensitive to image noise.
Furthermore, for the estimation of brain volume, this robustness offers substantial
benefits.
In the work presented here, an atlas-based approach was employed, which involved
affine coregistration of the pre-segmented MRI templates (atlases) to the target
image. Individual registration of multiple templates is known as multi-atlas
segmentation, which is a topic that will be discussed in greater detail in the following
section. After the registration step, the brain masks (labels) for the atlases were
transformed to the target image space. These labels then need to be combined in a
process known as label fusion (see section 3.12). Two methods were tested for label
fusion: STAPLE(159) and majority voting. The majority voting method was visually
better, possibly due to the small number of atlases used in this work. The advantages
of using affine coregistration over non-rigid registration are that the high-degree of
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regularisation renders the affine method robust to noise (Figure 14) and also affine
coregistration is typically fast and can be achieved with computational time of
approximately 1 min per atlas on 3D volumes with a 256×256×256 matrix size using
the freely available NiftyReg software package
(http://cmic.cs.ucl.ac.uk/home/software/)(160). The brain masking algorithm
described above was implemented in MATLAB.
Figure 14: Example of brain masking based on affine registration. This
algorithm can be used to estimate brain volumes even when imaging artifacts
lead to regions low signal to noise ratio (shown in the cerebellum).
3.11 Multi-Atlas Segmentation
In this project, I am interested in using volumetric MRI as an objective measure of
brain injury. There are several advantages of using MRI over histology for this
purpose. For instance, MRI can acquire data across the whole brain in 3D, whereas
unbiased stereological procedures are needed in histology to extrapolate from
multiple tissue sections(161). Furthermore, MRI can be carried out in vivo, allowing
access to longitudinal data. In order for these methods to be achievable, automated
methods of analysis are needed as manual segmentation on high-resolution 3D
datasets is hugely laborious. In this section it is shown that highly accurate automatic
segmentation of the rat hippocampus can be achieved using a number of already
manually segmented datasets. This method is called multi-atlas segmentation and is
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currently one of the most accurate techniques available for image segmentation(162-
164). Multi-atlas segmentation is an extension of the single-atlas method (in which a
single parcellated template is registered to the target image). Another method might
be to use a probabilistic framework to incorporate many delineated images into the
segmentation. However, in order to gain full advantage of the a priori information
that is available, registration to the target image should be performed separately for
each of the individual templates in what is known as multi-atlas segmentation.
3.12 Cross-Validation of Automated Hippocampal Volume Measurements
Once the registration has been performed, each atlas has assigned a label to the target
image. The combination of these labels is known as label fusion and several different
solutions to this problem have been proposed. The simplest of these is the majority
voting algorithm, which simply accepts the label that has the largest number of votes.
Another popular method of label fusion is the Simultaneous Truth And Performance
Level Estimation (STAPLE) algorithm(159). Algorithms that perform the best are
those which use global and/or local similarity measures to compare the templates and
the target image. For this reason, we have chosen to use the Similarity and Truth
Estimation for Propagated Segmentations (STEPS) method, which has been shown to
outperform most other freely available label fusion methods for segmentation of the
human hippocampus(165) and is freely available in the NiftySeg software package
(http://cmic.cs.ucl.ac.uk/home/software/). STEPS is based on using local cross-
correlation as a similarity measure for locally selecting the templates which most
closely correspond to the target image.
In order to evaluate the accuracy of this method and at the same time optimise the
two label-fusion parameters (width of the Gaussian kernel size (k) for cross-
correlation and number of atlases), cross-validation was performed using leave-one-
out cross validation (LOOCV). LOOCV involves testing the automated algorithm on
one MRI volume, whilst using the rest of the dataset as training data (atlases). This is
repeated on each observation sequentially in order that each observation is used once
for validation and the result from each validation step is averaged.
Preliminary imaging experiments were conducted as part of the pilot experiment
outlined in section 3.1. 24 3D FSE datasets were used for LOOCV. These datasets
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were from rats imaged prior to SE (n=16) and rats imaged 3 weeks after SE (n=8).
The imaging parameters were the same as those shown in Figure 15d. Manual
segmentation was used for delineation of the hippocampus and was used as the
ground truth for calculation of Dice scores. Dice scores are used here as a measure of
segmentation accuracy and were calculated using equation 18:
18
where and are the number of pixels assigned as hippocampus for the
automatic and manual segmentations respectively and is the number of
pixels assigned as hippocampus by both automatic and manual methods.
The 3D FSE images were first brain extracted using the method described in section
3.10 and then intensity normalisation was carried out using the method described in
section 3.9. After this, every template was registered to every other, firstly by affine
registration and followed by non-rigid registration based on free-form deformation
using B-splines(166). This was procedure was conducted using the NiftyReg
software package. LOOCV and label fusion optimisation was then implemented
using a range of label fusion parameters. This was done by adapting a shell-script
written by Ma Da from the Centre for Advanced Biomedical Imaging at UCL. The
results from this cross-validation can be seen in Figure 15, which crucially
demonstrates that both the atrophied (Figure 15c) and healthy (Figure 15b)
hippocampus can be segmented with a high degree of accuracy. Using the optimum
label fusion parameters for the post-SE rat brain, which were: number of atlases=7
and k=4, the mean Dice score (±standard error of the mean (SEM)) was 0.89±0.0002
for controls and 0.88±0.006 for post-SE rats with hippocampal injury.
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Figure 15: Leave-one-out parameter optimisation for label fusion
algorithm. Number of atlases vs. Dice Score plotted for different Gaussian
kernel size (k). Dice scores were calculated between manual segmentation and
the proposed method. (a) Including all test datasets (n=24). (b) Including only
healthy controls (n=16). (c) Including only post-status epilepticus rats (n=8).
3.13 Spatial Normalisation and Statistical Parametric Mapping
The use of ROIs for measurement of image intensities or other parameters is
convenient as it can be used to provide anatomical labels. However, the use of ROIs
may also sacrifice sensitivity due to partial volume effects. The risk of this is
particularly high in the case where the effect of interest is much smaller than the ROI,
e.g. within cell layers of the hippocampus. Using smaller ROIs may circumvent this
problem to some extent, but accurate methods of parcellation are necessary in order
for these regions to be positioned. One method around this approach is to use spatial
normalisation. Spatial normalisation can be performed by coregistration of all images
to an atlas, or by performing group-wise registration to create a population-specific
template. One of the issues with creating a population specific template is the risk
that the group-wise registration can be biased to one of the subjects or groups in the
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analysis. This problem can be addressed by continually repeating the registration to
the population mean. The initial template image also needs to be selected and can
introduce some bias into the final template.
After spatial normalisation has been performed, statistical analysis can be performed
on a voxel-wise basis. If parametric statistics are used, this method is called
statistical parametric mapping. One of the major issues with this approach is that
testing each voxel independently leads to an increased risk of Type I errors (false
positives). On the other hand, voxels are likely to be highly correlated and therefore
adjusting the significance level using the Bonferroni correction is normally too
conservative and leads to Type II errors. Application of this approach to T2 mapping
has been termed voxel-based relaxometry(167).
The most common method for spatial normalisation is the approach implemented in
SPM (http://www.fil.ion.ucl.ac.uk/spm/). This involves firstly, segmenting images
into three (or more) different tissue classes: grey matter, white matter and
cerebrospinal fluid (CSF). Segmentation in SPM is performed using a unified
approach(168) that incorporates both bias-field correction and prior information on
tissue classes. In order for tissue class segmentation to perform well, the tissue priors
should be study-specific. Each voxel is modelled using a mixture of Gaussians and
an iterative Expectation Maximisation algorithm is used to optimise the mixture
parameters, bias field and deformation of the tissue class probability maps.
Following segmentation, tissue classes can then be non-linearly registered to the
evolving group-wise average tissue class probability map using DARTEL
(Diffeomorphic Anatomical Registration using Exponentiated Lie algebra)(169).
This approach to spatial normalisation is the same as that which is implemented in
the most recent voxel-based morphometry (VBM) methods. VBM is a highly
sensitive technique used to compare local concentrations or volumes of grey
matter(148).
3.14 Summary
This chapter has outlined the development of experimental and image analysis
protocols. Firstly, preliminary experiments were conducted in the lithium-pilocarpine
61
model. These experiments indicated that administration of lithium nearer to
pilocarpine injections ensures a higher proportion of animals reach SE.
Experimental work was presented that outlined the development of a structural
imaging protocol and these datasets were used to optimise automated methods of
whole brain and hippocampal volume measurements.
The theory behind using gradient-echo imaging for the detection of iron oxide
contrast agents was provided. The next chapter is concerned with in vivo imaging of
cerebral inflammation using iron oxide contrast agents.
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Chapter 4 Molecular Imaging of Inflammation
4.1 Aims
The previous chapter described how superparamagnetic iron oxide particles can be
used as a contrast agent for MRI. It was also discussed how the gradient-echo pulse
sequence is suited to detection of iron oxide as it is sensitive to magnetic field
inhomogeneities. The aim of the current chapter is to determine the feasibility of
using iron oxide particles for imaging cerebral inflammation. A secondary aim will
be to characterise this imaging agent by determining the optimum dose for in vivo
imaging and investigating its blood clearance rate and biodistribution.
4.2 Molecular Imaging of Cerebral Inflammation
Cerebral inflammation occurs in various neurological conditions such as stroke,
epilepsy, traumatic brain injury, brain tumours and Alzheimer’s disease. In these
conditions it is known that some inflammatory processes are beneficial and promote
repair, whilst others are detrimental. The inducible cell adhesion molecules are key
mediators of diapedesis (migration of blood cells through blood vessel walls) and
could therefore be used as biomarkers for monitoring anti-inflammatory therapies
following brain injury. Recently, imaging vascular cell adhesion molecule-1
(VCAM-1) expression using micron-sized particles of iron oxide (MPIO) coupled
with MRI has shown to be an extremely sensitive and highly specific method of
detecting and locating inflammation(170-176). The low constitutive expression of
VCAM-1 renders it an ideal target for molecular imaging. It is expressed on the
surface of endothelial cells within blood vessels, and therefore can be used to
monitor pathology or therapies in the brain without the need for contrast agents to
cross the blood brain barrier. VCAM-1 mediates the rolling and extravasation of
leukocytes across the vascular endothelium(177). Furthermore, it is thought to play a
key role in several pathological conditions and may therefore provide a meaningful
biomarker of disease progression. For example, it has been suggested that VCAM-1
is used by tumour cells to aid adhesion to the vascular endothelium(178) and section
1.8.8 describes how its expression may exacerbate ictogenesis or the development of
epilepsy (epileptogenesis).
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rates and biodistribution. In vivo assessment of contrast agent binding was achieved
using a model of cerebral inflammation in which TNF-α was administered to one 
cerebral hemisphere of the brain. This experiment also enabled us to find the
approximate concentration of CA required for imaging. Both MRI and single-photon
emission computed tomography (SPECT) were then conducted in order to assess the
capacity of each of these imaging methods to detect presence of the contrast agent in
vivo.
4.4 Materials and Methods
4.4.1 Contrast Agent Synthesis
Monoclonal antibodies specific to rat VCAM-1 (MR106) (ebioscience, San Diego,
CA) were conjugated to micron-sized (1 µm diameter) iron oxide particles (MPIO,
Invitrogen, Life Technologies, U.K.) via the tosyl coupling reaction (Figure 17)
using the method described in the manufacturer’s specifications. The final product
was anti-VCAM-1 antibodies bound to MPIO and henceforth will be referred to as
VCAM-MPIO for consistency with the literature. To control for non-specific binding,
non-specific IgG antibodies (Southern Biotech, Birmingham, AL) were used in place
of anti-VCAM-1 antibodies to generate the IgG-MPIO control CA.
Figure 17: Tosyl conjugation of micron-sized iron oxide particles to free
primary amine groups on antibodies.
4.4.2 In vitro experiment
The immortalised rat brain endothelial cell line (GPNT) was generously provided by
Prof. John Greenwood, Institute of Ophthalmology, University College London.
GPNT cells were cultured until conﬂuent in 35 mm diameter well dishes. Cells were 
treated with 10 ng/ml human recombinant TNF-α (Invitrogen, UK) (n=3) or saline 
(n=3) in controls and incubated at 37°C for 20 h. VCAM-MPIO was added at a
concentration of 0.06 mg/ml media and cells were incubated for 2 h at 37°C then
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washed several times with PBS (pH 7.4). Quantitation of contrast agent binding was
performed on grayscale images by thresholding at an arbitrary value. Data is
displayed as mean±SD.
4.4.3 Radiolabelling
For the in vivo characterisation of the MRI contrast agent, the CA was radiolabelled
using 125I. VCAM-MPIO was re-suspended in heparinised phosphate-buffered saline
(PBS) (100 µl) and radiolabelled using 30-150 MBq of [125I]NaI (PerkinElmer,
Billerica, MA). This radiolabelling was carried out by Niral Patel from the Centre for
Advanced Biomedical Imaging, UCL, using pre-coated 1,3,4,6-tetrachloro-3α,6α-
diphenylglucoluril (Iodogen) tubes (Thermo Fisher Scientific, Rockford, IL), at room
temperature for 30 minutes. After this time, the radioactive mixture was purified by
magnetic separation to remove any unbound 125I. The washing and purification step
was repeated five times. This method incorporates iodine onto the tyrosine groups on
the antibody. It is plausible that it also reduces the binding affinity of the iron oxide
particles to the target antigen.
4.4.4 In vivo experiment
All animal procedures were carried out in accordance with the UK Animals
(Scientiﬁc Procedures) 1986 Act and institutional ethics regulations. Adult male 
Sprague-Dawley rats weighing 170-200 g were anaesthetised using a combination of
isoflurane (1% in oxygen) and urethane (1.5 g/kg) as the latter can provide stable,
long-lasting anaesthesia(179).  300 ng tumour necrosis factor alpha (TNF-α) in 5 µl 
saline was injected into the right striatum using a Hamilton syringe attached to a 31G
needle. Saline was administered in control subjects. Radiolabelled VCAM-MPIO or
IgG-MPIO was administered 7 h following TNF-α or saline administration via a 
cannula inserted into the right external jugular vein.
4.4.5 SPECT/CT
In vivo SPECT/CT (computed tomography) was performed under isoflurane (1% in
oxygen) and urethane using a nanoSPECT system (Bioscan Inc., Washington D.C.)
approximately 20 min post contrast administration. A physiological monitoring
system (SA Instruments, Stony Brook, NY) was used to monitor respiration rate and
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rectal temperature. Temperature was maintained at 37±0.5°C using an air warming
system. A CT scan was conducted with the following parameters: radial field of
view (FOV)=40.5 mm2, axial field of view=40.9 mm, exposure time per
projection=1 s, 360 projections and 55 KvP tube voltage, which resulted in an
acquisiton time of 6 minutes. The same FOV was used for helical SPECT, using 2.5
mm pinhole apertures, an exposure time of 15 s per projection and 20 projections
resulting in an acquisition time of 5 min.
4.4.6 Magnetic resonance imaging
In vivo MRI was performed using a 9.4 Tesla DirectDrive VNMRS horizontal bore
system with a shielded gradient system (Agilent technologies, Palo Alto, CA) and a
4-channel rat head phased-array coil (Rapid Biomedical GmbH, Würzburg,
Germany). A physiological monitoring system (SA Instruments, Stony Brook, NY)
was used to monitor respiration rate and rectal temperature. Temperature was
maintained at 37±0.5°C using an air and water tubing warming system. MRI was
performed approximately 1 h following contrast agent administration. Iron oxide was
detected using a 3D gradient echo sequence (TR=100 ms, TE=11 ms,
matrix=192×192×160, FOV=24×24×26 mm3, acquisition time51 min).
4.4.7 Blood clearance
Blood samples (n=3) were collected from the jugular vein cannula at different time
points following tracer administration. After each collection, the cannula was flushed
with saline to remove traces of radioactivity. The radioactivity present in the blood
samples collected was subsequently measured in a Wizard 2470 Automatic gamma
counter (PerkinElmer). Results are expressed as a percentage of injected dose per
gram.
4.4.8 Ex vivo biodistribution
Adult male Sprague-Dawley rats weighing approximately 200 g (n=3) were
anesthetised using isoflurane (4% in oxygen). Radiolabelled contrast agent (5 mg/kg,
8-10 MBq) was administered via the lateral tail vein 10 min after CA administration.
Blood was sampled via cardiac puncture before sacrificing the animals. The organs
67
of interest were removed, and measured using a gamma counter. Results are
expressed as a percentage of injected dose per gram ± standard error of the mean.
4.4.9 SPECT Reconstruction
SPECT images were reconstructed using the HiSPECT software package (Bioscan,
Washington, USA) using the following parameters: smoothing=45%,
resolution=67%, iterations=10. CT reconstruction was performed using InVivoScope
(InviCRO, Boston, MA).
4.4.10 MRI Quantification of Contrast Agent Binding
Brain extraction was performed using the Brain Extraction Tool (BET) in FSL(158).
Hypointensities caused by the presence of iron oxide were segmented using adaptive
thresholding in order to take into account local variations in signal intensity. This
was achieved by subtracting the MRI volume from the volume convolved with a 3-
dimensional Gaussian kernel of size 15×15×15 voxels, followed by thresholding
with the same empirically determined threshold used across all datasets. Regions of
interest were defined as the entire (left or right) cerebral hemisphere across 30
consecutive slices anterior and 30 slices posterior to the injection site, thus excluding
the cerebellum. CA binding was expressed as the percentage of total ROI volume.
4.4.11 SPECT Quantification of Contrast Agent Binding
Brain extracted MRI images were coregistered to the CT images and ROIs were
propagated into CT native space using the same transformation. In this way, identical
ROIs were used for both the MRI and SPECT analysis. Background signal intensity
was defined as the mean signal intensity across all non-brain tissue and CA binding
was expressed as the target-to-background ratio to account for the large range of
radioactivity used.
4.4.12 Coregistration
Rigid coregistration of MRI and CT images was performed in AMIRA®
(Visualization Sciences Group, Burlington, MA) on the gradient-echo images of the
brain extracted MRI magnitude data and the CT intensity images using normalised
correlation as the cost function. SPECT images were realigned to CT images using
rigid registration with normalised mutual information as the cost function in the
InVivoScope software package.
4.4.13 Statistical Analysis
Statistical analy
tests. Statistical significance was assigned at p<0.05.
4.5 Results
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contrast is exhibited at 5 and 6 mg Fe/kg (Figure 20d,e). Noticeably more CA
binding was observed in TNF-α treated animals (Figure 20d) compared to controls 
(Figure 20a,b), which could be demonstrated using in vivo quantitation using MRI
(Figure 21 a) and SPECT (Figure 21b). Local thresholding performs well for the
segmentation of hypointense regions (Figure 20f,g,h) There was a significant
difference between the group means in the affected hemisphere as assessed by MRI
(p<0.0002) but this did not reach the significance level for the SPECT quantitation
(p=0.1). CA was localised predominantly to the affected (right) cerebral hemisphere
in TNF-ɑ treated animals (Figure 20h) and contrast volume in the right hemisphere 
was significantly different from the left cerebral hemisphere based on the in vivo
MRI quantitation (p<0.02) (Figure 21a). This distribution of CA binding can be seen
in the 3D reconstruction (Figure 23b).
Coregistration of CT and MRI using cross-correlation performed particularly well
when the MRI (brain extracted) gradient images were used (Figure 22c,g), for the
reason that the majority of contrast from CT images is between the skull and soft
tissue. Following coregistration, good colocalisation can clearly be observed between
hypointensities on MRI images and hyperintensity on SPECT images (Figure 22h).
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energy gamma ray emitter used in this study. From the synthesis perspective, the
presence of superparamagnetic iron oxide makes purification of the radiotracer fast
and straightforward. Along with this, the short radiolabelling time (30 minutes) and
high radiochemical yields (>80%) demonstrate how this synthetic method would be
highly beneficial for radioisotopes with shorter half-lives. Iodine-125 was selected
for this study as it offers straightforward and reliable labelling. Nevertheless, an
isotope that can be chelated onto the iron oxide construct might render the probe
more stable.
Ex vivo biodistribution studies showed uptake of the radiolabelled probe in organs
known to be involved in clearance of iron oxide particles from the blood. The high
accumulation in the lungs is likely to reflect obstruction of the pulmonary
vasculature, whilst high liver and spleen uptake is due to clearance of particles by the
reticuloendothelial system. A similar pattern of distribution was observed on in vivo
images, however a high lung uptake was not detected. The discrepancy between
these results is likely due to the fact that in the biodistribution study data is reported
as a fraction of the tissue mass (percentage of injected dose/g) and SPECT imaging
reflects activity per volume.
Radiolabelled VCAM-MPIO was almost completely cleared from the blood within 2
minutes. This rapid clearance demonstrates that in order to avoid signal from free
MPIO in the blood, in vivo imaging can be performed soon after administration of
the radiolabelled CA. Nanoparticles typically show clearance rates on the order of
hours and so these results suggest that micron-sized particles could lead to higher
signal-to-background ratios than nanoparticles because the bound contrast agent will
also be cleared at a rate which is on the order of hours(170). The presence of 0.2%
ID/g in the blood even after 10 min indicated the possibility that free iodide was
present or that circulating macrophages took up some of the MPIO from the blood.
This study has shown that particulate-based contrast agents can be used to deliver
large quantities of radiotracers to the vasculature of the brain. Using nano- or
micron-sized constructs has numerous advantages over small molecular weight
agents when it comes to targeting the vasculature. These include: fast blood
clearance, reduced non-specific binding and high sensitivity. The presence of a
nuclear imaging probe over and above the iron oxide contrast agent could be used in
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the future to assess the kinetics of ligand dissociation and provide more accurate
quantification of contrast agent binding.
MRI can be seen to offer some advantages over nuclear imaging in this technique,
particularly with regard to partial volume effects and lower background signal. The
comparison in sensitivity between the two modalities is naïve as relatively low doses
of a low energy emitter are used in this work. 125I decays by emission of gamma rays
with a maximum energy of 35 keV. In contrast, the positron emission tomography
(PET) tracer 18F decays to form positrons, which release high energy (511 keV)
gamma rays on annihilation. SPECT offers some advantages over MRI with
paramagnetic iron contrast in that it confers positive contrast, is quantitative and also
can be multiplexed i.e. radioisotopes with different photon emission energies can be
used in a single experiment and distinguished from one another in vivo.
4.7 Conclusions
In conclusion, this study has demonstrated the feasibility of performing bimodal
imaging of cerebral inflammation using SPECT and MRI and has enabled a
comparison between the two techniques. Without further optimisation, detection of
CA using MRI appears to be superior to SPECT in terms of sensitivity. This is
surprising but could be owing to a number of factors, such as: the background signal
in the blood reducing the sensitivity of the nuclear imaging, signal attenuation from
tissue absorption of the low energy gamma rays and possibly also due to the more
limited resolution of SPECT resulting in partial volume effects. The higher
background signal might be due to instability of the nuclear imaging tracer and
therefore improving this might lead to enhancements in sensitivity. This study has
found that approximately 5 mg of iron per kg appears to be appropriate for in vivo
imaging of cerebral inflammation in the rat based on the compound synthesised here
and also that blood clearance of MPIO is extremely rapid so that imaging can be
performed soon after injection to maximise contrast. This information will be helpful
for the next chapter in which imaging of seizure-induced inflammation is attempted.
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Chapter 5 Imaging Seizure-induced Inflammation
5.1 Aims
The previous chapter showed that using iron oxide particles coupled with MRI
provides an extremely sensitive method of detecting cerebral inflammation. Cerebral
inflammation was induced by direct intracerebral injection of a pro-inflammatory
cytokine. In this chapter it is hypothesised that it is possible to detect the cerebral
inflammation that occurs following status epilepticus. Parts of this chapter have been
published(181) and are reproduced with permission from Elsevier (copyright 2012).
5.2 Introduction
As mentioned in section 1.7, there is mounting evidence to suggest that inﬂammation 
may be involved in ictogenesis and also the development of some partial epilepsies.
Non-invasive imaging of inﬂammation would enable tracking of the temporal 
progression of inﬂammation following epileptogenic insults. The previous chapter 
discusses how VCAM-1 conjugated to micron-sized iron oxide particles is ideally
suited as an imaging agent due to the low background expression of VCAM-1 in
normal healthy tissue and the ability of these particles to deliver a large payload of
iron. Section 4.2 noted that VCAM-1 plays a role in leukocyte adhesion. As
leukocyte adhesion is correlated to BBB permeability(182), we hypothesise that
VCAM-1 expression occurs prior to vasogenic oedema and the associated T2
changes(44, 183). Imaging VCAM-1 expression could therefore provide an early and
more sensitive marker of inﬂammation or subtle alterations in blood-brain barrier 
permeability that cannot be detected clinically using gadolinium based contrast
agents(178) or T2 weighted MRI(171). In this study, an attempt is made to image
seizure-induced endothelial activation using micron-sized particles of iron oxide
conjugated to anti-VCAM-1 antibodies (VCAM-MPIO) soon after termination of
lithium-pilocarpine induced status epilepticus in rats.
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5.3 Materials and Methods
5.3.1 Animal Model
All animal procedures were carried out in accordance with the UK Animals
(Scientiﬁc Procedures) 1986 Act and institutional ethics regulations. Adult male 
Sprague-Dawley rats weighing 180-230 g (n=12) were obtained from the breeding
colony of the University College London Animal Facility. All rats were housed in a
controlled temperature and humidity environment with a 12 h light/dark cycle with
food and water provided ad libitum. Animals were separated into three groups:
Lithium-pilocarpine control group which did not undergo status epilepticus given
VCAM-MPIO contrast (ControlVCAM) (n=4) (Figure 24a), lithium-pilocarpine
induced status epilepticus with IgG-MPIO contrast agent to control for non-speciﬁc 
binding and leakage through the blood brain barrier (SEIgG) (n=3) (Figure 24b) and
lithium-pilocarpine induced status epilepticus with VCAM-MPIO contrast (SEVCAM)
(n=5) (Figure 24c).
It has been previously shown that lithium and pilocarpine may directly cause
peripheral inﬂammation(184), and could conceivably also directly lead to central 
nervous system (CNS) inﬂammation. To control for this effect, the control group 
received diazepam (10 mg/kg, i.p.) injections prior to the injection of lithium and
pilocarpine (Figure 24a). Injection of diazepam prior to the injection of pilocarpine
has shown to completely prevent the development of SE(185).
In the SEVCAM group (Figure 24c) and SEIgG group (Figure 24b), animals were
pretreated with lithium chloride (3 mEq/kg, i.p.) 2 h prior to methylscopolamine (5
mg/kg, i.p.) injection. Methylscopolamine was administered to reduce the peripheral
effects of pilocarpine. This was followed 20 min later by administration of
pilocarpine hydrochloride (30 mg/kg, i.p.) in order to induce status epilepticus.
Animals were behaviourally assessed on using the Racine scale (section 1.5.6).
Diazepam (10 mg/kg, i.p.) was administered 90 min after the onset of SE to
terminate the seizure. Further injections of diazepam were administered as required.
The ControlVCAM group (Figure 24a) received a lithium chloride injection (3 mEq/kg,
i.p.), a subsequent injection of diazepam (30 min prior to pilocarpine injection) to
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prevent SE onset(185), followed by methylscopolamine (20 min prior to pilocarpine
injection) and pilocarpine (30 mg/kg).
Figure 24: Study design showing the three treatment groups.
(a) ControlVCAM group received a single diazepam injection in order to prevent
SE and received VCAM-MPIO contrast agent. (b) SEIgG group underwent status
epilepticus and received a control contrast agent IgG-MPIO. (c) SEVCAM group
underwent status epilepticus and received VCAM-MPIO contrast agent.
5.3.2 In vivo MRI
MRI was performed using the system described in section 4.4.6 before and after
injection of the contrast agent. Animals were anesthetised with 4% isoflurane and
maintained at 1.5-1.6% isoflurane in pure oxygen (1 L/min) throughout the imaging
protocol. A physiological monitoring system was used to monitor respiration rate and
rectal temperature. Temperature was maintained at 37±0.5˚C using an air warming 
system. VCAM-MPIO (4 mg of iron/kg) was injected via a cannula inserted into the
right external jugular vein 21.9±0.2 h post-SE onset or 22.1±0.2 h post-pilocarpine
administration in control subjects. Animals were imaged 1 h post CA administration.
The imaging parameters were as follows: 3D spoiled gradient-echo, TR=100 ms,
TE=6.5 ms, FA=30º, matrix=192×192×128, FOV=22×22×20 mm3, acquisition
time=40 min. The images were zero filled to 256×256×256, giving a final voxel size
of 86×86×78 µm3. T2 measurements were performed before injection of the contrast
agent with a multislice multi-echo spin-echo sequence across 13 contiguous slices:
TR = 2 s, TE=8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104, 112, 120 ms,
matrix = 128×128, FOV=25×25 mm2 slice thickness=1 mm, acquisition time=4 min.
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5.3.3 Ex vivo MRI
Approximately 4 h after contrast agent injection, animals were perfused-fixed with
50 ml PBS (pH 7.4) followed by 50 ml paraformaldehyde (PFA) (4% in PBS, pH
7.4) via a cannula inserted into the left ventricle. The brains were removed and
immersed in PFA (4%) overnight. The fixed-brains were immersed in Fomblin (type
PFS-1, Solvay Solexis S.p.A., Bollate, Italy) for ex vivo MRI using a 26 mm
diameter birdcage coil (Rapid Biomedical GmbH). The imaging parameters were as
follows: 3D SPGR, TR=350 ms, TE=9.8 ms, FA=60º, matrix = 300×300×300,
FOV=20×20×20 mm, total acquisition time=8 h 45 min. The images were zero-filled
to 512×512×300 and then downsampled to 512×512×150 giving a final voxel size of
39×39×133 μm3.
5.3.4 Segmentation of contrast volume and T2 analysis
The brain was manually segmented on gradient-echo images on 40 contiguous slices.
Regions were classified as hypointense using an automated segmentation algorithm
implemented in MATLAB. This was similar to the approach described in section
4.4.10. Firstly, intensity scaling was conducted using equation 17 to transform
intensity values to within the range 0 and 1. Hypointense regions were thresholded if
they were less than the local median-C, where C is an empirically determined
constant. The local median was calculated using a 3D median filter with a radius of 5
voxels. Nearest neighbour connectivity was then determined in 3 dimensions (objects
were defined as connected if they shared at least one vertex) on the thresholded data
and objects were discarded if the object size was below a threshold cluster size of 4
voxels as these were likely to be due to noise. Quantitative T2 measurements were
performed using the multi-slice multi-echo spin-echo sequence data by calculating
power images (section 2.3) and fitting a single exponential decay to the mean signal
across a ROI using the non-linear least squares function in MATLAB. The first two
echo times were excluded from the analysis as this minimised errors resulting from
stimulated echoes and produced a better fit to a mono-exponential function. For both
datasets ROIs were drawn by an observer blinded to the animal groupings over 4
different brain regions including the dorsal hippocampus, cerebral cortex, thalamus
and piriform cortex using a standard rat brain atlas(186).
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5.3.5 3D reconstruction
3D reconstruction was conducted on separate in vivo datasets acquired 2 h post
contrast administration. Hypointense regions were segmented using the same
algorithm as above. The imaging parameters were as follows: 3D spoiled gradient-
echo, TR=100 ms, TE=11 ms, FA=15º, matrix=192×192×128, FOV=25×25×20 mm3.
The images were zero filled to 256×256×192.
5.3.6 Statistical analysis
Unless otherwise stated, Differences between groups were compared using the non-
parametric Kruskal–Wallis test and Wilcoxon rank-sum tests. Statistical significance
was assigned at p<0.05. Data is displayed as mean±SEM.
5.4 Results
5.4.1 Animal Model
All animals in the SEVCAM group and the SEIgG group progressed to status epilepticus.
All animals displayed akinesia and facial automatisms which progressed to tonic–
clonic seizures and status epilepticus within 60 min of pilocarpine administration.
None of the animals in the control group displayed any signs of behavioural seizures.
Mean Racine seizure scores (n=3) following SE onset were: 0–30 min=3.2±0.2, 30-
60 min=4.1±0.2, 60–90 min=4.7±0.4.
5.4.2 Magnetic Resonance Imaging
Hypointense regions caused by VCAM-MPIO binding are clearly present on the in
vivo MRI images in the SEVCAM group and appear to be maximal in the
periventricular organs (Figure 25c). Additionally, hypointense regions also appear to
be present predominantly in the hippocampus and the cerebral cortex on in
vivo images. Hypointensities were not identified in these regions in the pre-injection
images. A similar distribution was observed on high resolution ex vivo 3D gradient-
echo images, corroborating that these hypointensities are caused by the VCAM
contrast agent. The ControlVCAM and SEIgG groups showed very few hypointensities
on MR images on both in vivo and ex vivo images, demonstrating that VCAM-1
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expression was seizure induced and also that there is little non-specific binding or
leakage across an impaired BBB (Figure 25a,b).
Figure 25: 3D gradient-echo images pre-contrast, post-contrast and ex vivo.
Coronal MR image slices of 78 μm thickness at approximately 3.8 mm posterior 
from the bregma are shown for a representative animal from each group. Images
were acquired 22 h after SE or pilocarpine administration, approximately 1 h
after contrast agent administration and ex vivo images were acquired at the end
of the study. (a) SEVCAM group rat receiving 4 mg iron per kg VCAM-MPIO.
Focal hypointense regions can be observed in the periventricular organs,
hippocampus and cerebral cortex both in vivo and ex vivo following contrast
agent administration. (b) ControlVCAM group which did not undergo status
epilepticus injected as in panel a, demonstrating an absence of contrast agent
binding. (c) SEIgG group administered with a control contrast agent IgG-MPIO
as in panel a. An absence of contrast agent demonstrates that there was little
non-specific binding or leakage through the impaired blood brain barrier.
5.4.3 Quantitation of the inflammatory response
Significantly more hypointense volume was observed in the hippocampus
SEVCAM group compared to the ControlVCAM group and the SEIgG control (Figure 26b)
(7.0±2.2% vs. 0.5±0.3% and 0.5±0.2%) (p=0.02). The volume of hypointensity
measured in the cerebral cortex was also significantly greater in the SEVCAM group
compared to control groups (10.5±4.6% vs. 1.1±0.6% and 1.2±0.5%) (p=0.02).
Hypointense volumes in the thalamus were much less marked than in the cerebral
cortex or the hippocampus (2.9±1.6% vs. 0.2±0.09% and 0.5%±0.2%) (p=0.02).
Three-dimensional reconstructions display this distribution of contrast agent binding
(Figure 27). Small amounts of hypointensity can be observed in the SEIgG group in the
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regions surrounding the ventricles and in larger blood vessels (Figure 27), this is
likely to reflect the limitations in distinguishing between the presence of contrast
agent and the differences in magnetic susceptibility in the normal brain (particularly
at high field strength), which usually present at air-tissue, tissue-cerebrospinal fluid
interfaces and large blood vessels. T2 measurements were not significantly elevated
in the SE group compared to the control group in the hippocampus, cerebral cortex,
or the thalamus (Figure 26a). T2 values were higher in the piriform cortex of the
SEVCAM group compared to the ControlVCAM group (81±6.2 ms vs. 55±0.41 ms) (p=0.02).
Figure 26: In vivo T2 measurements and quantitation of iron oxide
binding.T2 measurements in the hippocampus, cerebral cortex, thalamus and
piriform cortex immediately prior to injection of VCAM-MPIO contrast agent
for three different groups: ControlVCAM (n=4), SEIgG (n=3), SEVCAM (n=5). (b)
Hypointense volume as a percentage of total region volume following injection
of VCAM-MPIO or control IgG-MPIO in the hippocampus, cerebral cortex and
thalamus. (c) Example segmentation of hypointense regions for coronal MRI
image approximately 5 mm posterior to the bregma. Lower image: segmented
regions overlaid in red.
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Figure 27: Imaging VCAM-1: three-dimensional reconstruction showing
hypointense regions. Segmented hypointense regions are shown in red.
Hypointensities were automatically segmented using a local thresholding
approach. (a) ControlVCAM rat following administration of VCAM-1 targeted
contrast agent. (b) SEVCAM rat which underwent status epilepticus approximately
22 h prior to contrast administration. Upper inset: surface rendered brain with
orientation planes: A-anterior, P-posterior, L-left, R-right. Lower inset: axial
slice for anatomical reference.
5.5 Discussion
In this study we have used antibody targeted superparamagnetic iron oxide particles
to track the distribution of VCAM-1 expression in vivo. This is the first study to
identify regions of inflammation following seizure induced inflammation using in
vivo MRI detection of VCAM-1. We have also demonstrated that binding of the
contrast agent occurred prior to the more commonly used MRI biomarkers (T2
measurements) of seizure induced brain injury. Our results suggest that there is
regional expression of VCAM-1 leading to focal hypointensities on MR images
following administration of a VCAM specific contrast agent. We observed maximal
contrast at the periventricular organs. This perhaps is to be expected as the
periventricular organs, which are incompletely protected by the blood brain barrier,
are thought to provide points of entry for proinflammatory cytokines into the
brain(187-189). Furthermore, hypointense regions are also clearly present in the
regions which are widely associated with neuronal damage following seizures, in
particular the hippocampus and the cerebral cortex appeared to be the most
significantly affected regions and to a lesser extent the thalamus. This distribution of
iron oxide could be readily verified from ex vivo MRI images demonstrating that this
is not confounded by partial volume effects.
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Our data suggest that seizure induced expression of VCAM-1 occurs primarily in the
regions which are most affected following status epilepticus. Synchronous neuronal
firing in the lithium-pilocarpine model appears to originate in the ventral forebrain or
limbic regions(185, 190, 191). Following this, spiking activity spreads to cortical
regions(185). Hypermetabolism and alterations in blood flow during SE in the
lithium-pilocarpine adult rat model occur primarily in the regions that suffer the most
significant neuronal damage (the cortex, anterior olfactory nuclei, all amygdaloid and
hippocampal regions, lateral septum, thalamic nuclei and substantia nigra)(44, 192-
194). Previously, increased VCAM-1 expression has been observed with
immunohistochemistry at 24 h following pilocarpine induced SE and remained
upregulated at 30 d(123). This is consistent with our data which demonstrate that
there is significant upregulation of VCAM-1 at 22 h post SE.
Evidence for regional expression of VCAM-1 is supported by in vitro studies which
have shown that seizure activity alone can cause increased expression of adhesion
molecules without the need for systemic effects(195). It has been previously shown
in the pilocarpine model that COX-2 is upregulated primarily in the hippocampus
and piriform cortex whilst expression of other mediators such as Toll-like receptor 2
(TLR2) and TNF-α have been found to be more global(196). In the focal kainate 
model, inflammatory markers such as upregulation of ICAM-1, microglia activation
and BBB disruption occur primarily in the ipsilateral (kainic acid injected)
hippocampus(197) This suggests that, seizure activity leads to the regional
expression of inflammatory markers. The cause of this regional expression is likely
to be complex and several factors might be involved, including seizure induced
release of high-mobility group box protein 1(69), necrosis, apoptosis and/or ischemia.
MRI T2 changes have been observed as early as 6 h following SE in the severely
affected piriform and entorhinal cortices(198). Hyperintensities in the hippocampus
are generally observed at a slightly later time point, with T2 measurements peaking at
about 48 h following SE in rodents(44, 183) and within 48 h in humans(199). It has
also been shown that T2 is predictive of neuronal injury following SE(200). However
in the current study we observed no significant increase in T2 in the hippocampus at
22 h following SE, yet marked binding of the targeted contrast agent. This suggests
that imaging inflammation using targeted iron oxide contrast agents could provide an
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early and more sensitive marker of brain injury. There is currently no validated
biomarker that predicts the development of epilepsy(201) and a molecular imaging
approach, such as reported here, could be used for this purpose.
The intra-vascular nature of the contrast agent used in this study may mean that iron
oxide induced contrast is dependent on the blood vessel density within voxels, which
is a possible limitation. Furthermore, distinguishing between hypointensities caused
by tissue interfaces and those caused by iron oxide based contrast agents is
problematic based on automated segmentation algorithms.
Recently it has been hypothesised that the post-seizure inflammatory processes in
these regions could contribute to both cell death and hyperexcitability(202). Studies
in epilepsy patients have indicated increased numbers of leukocytes in the brain
parenchyma compared to controls(123). However current therapeutic strategies are
only targeted towards treating neuronal excitability using anti-epileptic drugs that do
not treat the possible detrimental effects of the inflammatory component of the
condition, which could lead to both seizure activity and neuronal degeneration.
Imaging inflammation in epilepsy patients using targeted iron oxide contrast agents
could therefore help determine which subtypes of patients might benefit from anti-
inflammatory therapies.
5.6 Conclusions
The precise role of neuroinflammation in the progression of SE associated injury is
unknown. There is therefore a need for more specific imaging markers of
inflammation. In this study we have demonstrated in vivo imaging of acute
inflammation following lithium-pilocarpine induced status epilepticus. Imaging
markers of inflammation in models of epilepsy could enable pharmacological
modulation and may therefore be used to determine the role of inflammation in
epileptogenesis and neuronal injury. Furthermore, imaging of inflammation in clinic
could help determine which patients might benefit from anti-inflammatory therapy.
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Chapter 6 Anti-Inflammatory Therapies for Neuroprotection
following Status Epilepticus
6.1 Aims
The previous two chapters have outlined the development of a molecular imaging
technique that will enable the monitoring of inflammation following status
epilepticus. In this chapter, it is hypothesised that the aforementioned method could
be used as a biomarker for monitoring anti-inflammatory therapies. The potential for
these drugs to offer neuroprotection following SE is also assessed. The primary
hypotheses for the work outlined in this chapter are:
 The corticosteroid – dexamethasone is able to modulate VCAM-1 expression
and this can be monitored by using the molecular imaging approach described
in Chapter 5 (part I).
 Dexamethasone administered following prolonged seizures alleviates the
progressive brain injury caused by SE and this can be measured by using
volumetric MRI (part II).
 Voxel-based analysis methods, such as statistical parametric mapping and
voxel-based morphometry can be used alongside the region-based methods
for monitoring anti-inflammatory therapies (part III).
6.2 Dexamethasone
Dexamethasone was chosen for its broad-spectrum anti-inflammatory effects,
because it is inexpensive compared to antibody-based therapies and is widely used in
clinic for alleviating vasogenic oedema. It is frequently used for patients with
primary and secondary brain tumours as well as to treat allergic reactions. For this
reason it is more clinically translatable than experimental therapies that are not yet
approved by the regulatory authorities. Its mechanisms of action were described in
section 1.8.7. Briefly, DEX supresses NF-κB transcription and therefore has the 
capacity to reduce the expression of cell adhesion molecules such as VCAM-1.
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6.3 Part I: Modulation of the VCAM-1 Biomarker
The aims of this pilot study were to test whether dexamethasone can be used to
modulate VCAM-1 expression following SE and to determine whether the
previously characterised MRI contrast agent can monitor these changes in expression.
6.3.1 Materials and Methods
Status epilepticus was induced in 4 adult male Sprague-Dawley rats as described in
5.3.1. 2 rats were included as control subjects and underwent the same injections as
the ControlVCAM group in Figure 24. Approximately 1 h following status epilepticus,
2 rats received injections of dexamethasone sodium phosphate (10 mg/kg) (SE-DEX).
24 hours later, MRI using the VCAM-MPIO contrast agent was performed as
described in sections 4.4.6 and image analysis was implemented as described in
section 4.4.10.
6.3.2 Results
Initially, attempts were made to quantify VCAM-1 expression using western blotting.
However, western blotting failed under denaturing conditions (i.e. conditions that do
not preserve the tertiary structure of the protein). Some banding was seen in western
blots done under non-denaturing conditions (data not shown), suggesting the primary
antibodies used in this application require the tertiary structure of the protein to be
intact. However, this did not prove to be suitable for quantitation.
The aim of this pilot study were to test whether dexamethasone can be used to
modulate VCAM-1 expression following SE. Although the number of subjects in the
study was small, there was no suggestion that contrast agent binding was reduced in
subjects treated with the drug. This can be seen in Figure 28b,c, in which it is evident
that there are large amounts of iron oxide present in the hippocampus in rats treated
with DEX and there does not look to be a significant reduction in VCAM-1
expression. The imaging in one of the SE subjects was started 1 hour later than the
other imaging sessions due to issues relating to the acquisition software, which
explains the reduction in CA binding in this subject (Figure 28b, lower panel).
Nevertheless, the results conclusively show a significant amount of CA binding in
hippocampus of SE-DEX rats. Quantitation across the whole brain is shown in
Figure 29
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relaxometry to investigate whether DEX is neuroprotective when administered
following SE. In this study, T2 relaxometry was used as a marker of brain oedema.
For T2 measurements, rats were imaged at 2 and 4 days following SE. High
resolution structural imaging was performed 3 weeks after SE in order to determine
the effect of DEX on later brain injury. The primary hypothesis in this study is that
dexamethasone reduces hippocampal injury as determined by volumetric imaging.
The secondary hypothesis is that DEX is able to reduce the acute cerebral oedema
that occurs at 2 days after SE as monitored by T2 relaxometry.
6.5 Materials and Methods:
6.5.1 Animal Model:
All animal procedures were carried out in accordance with the UK Animals
(Scientiﬁc Procedures) 1986 Act and institutional ethics regulations. 
6.5.2 Experiment 1:
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich, UK. Male
Sprague-Dawley rats (170-210 g) were obtained from Charles River Laboratories
(Margate, UK) (n=42) and were kept under controlled environmental conditions
including a 12 h light-dark cycle and the provision of with food and water ad libitum.
SE was induced as described in section 5.3.1. Saline was administered in control
animals in place of pilocarpine (n=4). Seizure severity was assessed every 10 min
using the Racine scale (section 1.5.6). Diazepam (10 mg/kg, i.p.) was administered
90 min following SE onset in order to terminate the seizure. Additional diazepam (10
mg/kg) was administered 30-40 min later. Following status epilepticus, rats were
randomly assigned to one of two groups: SE-DEX10 rats (n=13) received
dexamethasone sodium phosphate (10 mg/kg, equivalent to 7.6 mg/kg
dexamethasone) immediately following status epilepticus and at 24 h (10 mg/kg)
following SE. This dose is comparable to doses that have shown or attempted to
demonstrate efficacy in other rat models of brain oedema(117, 203-206). SE rats
(n=15) received saline injections in place of dexamethasone. Dexamethasone is
known to have a diuretic effect(207), therefore SE-DEX10 and SE animals received
subcutaneous saline and saline/glucose solution for the first few days following SE.
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6.5.3 Experiment 2:
As a high mortality rate was observed in the SE-DEX10 group, the experiment was
repeated using the same protocol except a single dose of dexamethasone sodium
phosphate (2 mg/kg) was administered i.p. at 1 h following SE (n=16). Following SE
rats were randomly assigned to one of two groups: SE (n=6) and SE-DEX2 (n=6).
6.5.4 Magnetic Resonance Imaging
MRI relaxometry was performed at 48 h and 96 h following SE. A subset of animals
in experiment 1 were scanned prior to SE induction (n=17) and all of these rats were
included in the analysis. High resolution structural imaging was conducted between
18 and 20 d following SE. All imaging was carried out using the 9.4T MRI setup
described in section 4.4.6. Animals were anesthetised with 4% isoflurane and
maintained at 1.5-2% isoflurane in pure oxygen (1 L/min) throughout the imaging
session. Temperature was maintained at 37±0.5°C using an air and water tubing
warming system. T2 measurements were performed across 15 contiguous slices using
a 2D multi-echo spin-echo sequence using the following parameters: TR=2.5 s,
FOV=25×25 mm, slice thickness=1 mm, matrix=128 x 128 and TE=8, 16, 24, 32, 40,
48, 56, 64, 72, 80, 88, 96, 104, 112, 120 ms. T2-weighted high resolution structural
imaging was done using a 3-dimensional fast spin-echo (FSE) sequence at 150 µm
isotropic resolution (TR=1.8 s, FOV=24×24×24 mm, matrix=160×160×160,
TEeff=41.8 ms, ETL=16, acquisition time=48 min).
6.6 Data Analysis
6.6.1 Quantitative T2
Regions of interest were identified by coregistration of the multi-echo images to a rat
brain MRI template(208). This was performed in SPM 8 (UCL Wellcome Trust
Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) using a 12 parameter
affine registration with normalized mutual information as the cost function.
Following coregistration, the transformation matrix was used to transform the
regions of interest (ROIs) to the image space. Regions of interest included right and
left somatosensory cortices, anterior dorsal hippocampus, caudate putamen, cingulate
cortices, piriform cortices and the thalamus. Automated segmentation of the rat brain
was achieved by rigid coregistration to a rat brain template. The accuracy of the
segmentation was verified visually and is shown in
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6.6.3 Statistical Analysis
The statistical analysis in this study was performed by Dr Kwok Pan Chun of the
School of Environment and Sustainability, University of Saskatchewan, Canada.
Unless otherwise stated, statistical analysis between groups was performed using
one-way ANOVA and unpaired t-tests with unequal variance in the R software
package (http://www.r-project.org, version 3.1-109.). Mortality between groups was
tested using the test of equal proportions in R. In order to account for correlation
between variables, T2 was compared across all regions by means of a linear-mixed
effects model using the lme4 package in the R environment(211). For all linear-
mixed effects models, rats were considered to be random effects, whereas treatment
groups, weights, study date and mortality were considered to be possible fixed
effects (i.e. explanatory variables). In a stepwise mixed effects model framework, an
initial model starting with T2 across all brain regions is used to identify significant
regions as the explanatory variables for hippocampal volume. Box and whisker plots
show the median, and first and third quartiles. The whiskers are drawn from the first
and third quartiles to the most extreme point not considered outliers. Outliers are
considered to be more than 1.5 interquartile ranges from either the first or third
quartile and are marked with a plus sign. Averages are expressed as the mean±SEM.
Statistical significance was assigned at p<0.05.
6.7 Results
The aims of experiment 1 were to test the effects of dexamethasone given following
SE at a dose of 10 mg/kg on T2 and hippocampal volume. Surprisingly, the results
from experiment 1 suggested that dexamethasone at 10 mg/kg had a detrimental
effect on both survival during the first week after SE and brain injury at 3 weeks. For
this reason, experiment 1 was repeated using a lower dose of 2 mg/kg DEX.
6.7.1 Animal Model
All of the rats that were administered pilocarpine progressed to status epilepticus.
None of the animals in the control group exhibited any behavioral change. 14 out of
54 (26%) animals died during or immediately after SE and were therefore excluded
from the study. There was no difference between the three groups: SE, SE-DEX2 and
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SE-DEX10 in regards to latency to SE onset (Figure 31a). Furthermore, there was no
difference in seizure severity according to the behavioural scoring (Figure 31b). All
rats were scored throughout each 10 minute time period. During the later stages of
status epilepticus almost all rats reached stage 5 on the Racine scale, during which
time seizure severity alternated between stages 3 and 5. Behavioural scoring after 80
minutes was 4.3, 4.8 and 4.3 for SE, SE-DEX2 and SE-DEX10 respectively. The two
doses of diazepam were effective at terminating SE in all rats and no overt signs of
sustained seizures could be observed within the following 24 h. Dexamethasone or
saline was administered at 1 h following diazepam injection, at this time point, rats
were lethargic but there were no signs of on-going seizure-like activity.
Figure 31: Behavioural assessment of status epilepticus in SE and SE-DEX
rats. (a): Latency to onset of status epilepticus. (b): Behavioural assessment of
seizure severity throughout status epilepticus. (a) and (b) SE (n=21), SE-DEX
10 mg/kg (n=13) SE-DEX 2 mg/kg (n=6). Data is displayed as mean±SD.
6.7.2 Mortality
Within the first week after SE, 3 of 21 subjects died in the SE group, 2 of 6 in the
SE-DEX2 group and 6 of 13 in the SE-DEX10 group. The proportion of rats that
died within the week following status epilepticus was therefore 0.14, 0.33 and 0.46
for SE, SE-DEX2 and SE-DEX10 respectively. The animals that died after the 2 and
4 day imaging time points were included in the analysis. Although these proportions
were not significantly different (p = 0.11), these data indicate that dexamethasone
may exacerbate mortality associated with status epilepticus.
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6.7.3 Time Course of T2 alterations
T2 is elevated at 48 h in SE rats compared to CTL in the hippocampus (52.1 ms vs.
45.6 ms, p=0.008, Figure 32a) and piriform cortex (69.5 ms vs. 51.0 ms, p=5x10-7,
Figure 32b). These alterations began to normalize by 96 h. This marked bilateral
hippocampal oedema is shown in Figure 33b. 4 animals in this study exhibited
marked unilateral oedema in the neocortex (Figure 33b) that was not present in
controls (Figure 33a). These can be seen as outliers in Figure 32e,f. MRI performed
at 3 weeks following the initial insult (Figure 33d) exhibits significant atrophy of the
hippocampus leading to enlargement of the lateral ventricles. Hypointense regions in
the CA1, CA3 and dentate gyrus of the hippocampus are evident (Figure 33d).
Hyperintense regions at the three week time point in the right neocortex (Figure 33d)
correspond to the regions of hyperintensity that occurred at 48 h following SE
(Figure 33b).
6.7.4 Effect of Dexamethasone on Acute Cerebral Oedema
One of the aims of this study was to test whether dexamethasone alleviates the
regional T2 caused by status epilepticus in the hippocampus and piriform cortex. The
mean T2 relaxation time at 2 days in the hippocampus was: 45.6 ms, 52.1 ms, 55.3
ms, 55.0 ms for CTL, SE, SE-DEX10 and SE-DEX2 respectively (Figure 32a). In the
piriform cortex, T2 at 2 days was: 51.0 ms, 69.5 ms, 74.3 ms and 75.2 ms for CTL,
SE, SE-DEX10 and SE-DEX2 respectively (Figure 32b). The SE-DEX10 group had
significantly higher T2 in the piriform cortex than SE at 2 days and 4 days (p=0.01,
p=0.04 respectively).
A linear mixed-effects model was also used to compare all 12 brain regions together
in the treatment groups to the CTL group in order to account for other possible
within-sample effects and repeated measures. SE-DEX10 was significantly different
to CTL at day 2 and day 4 (p=0.004 and 0.03), DEX2 was significantly different to
CTL on day 2 (p=0.01) but not day 4 and SE was not significantly different from the
CTL group at either time point.
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Figure 32: T2 relaxation times measured pre, 48 h and 96 h following
lithium-pilocarpine induced status epilepticus. (a) Hippocampus, (b) Piriform
Cortex, (c) Thalamus, (d) Caudate Putamen, (e) Primary Somatosensory Cortex,
(f) Cingulate Cortex. Treatment groups: CTL (n=4), SE (n=20), SE-DEX10
(n=10), SE-DEX2 (n=4).
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6.7.5 Effect of Dexamethasone on Relative Hippocampal Volume and Total
Brain Volume
Accurate segmentation of the hippocampus was achieved in MRI images of both
controls and post
At 3 weeks following status epilepticus, rHCV was significantly different among
groups (Figure
volume compared to CTL (p
compared to SE (p=
and SE. Total brain volumes were 2612.8±40.4 mm
mm3 and 2521.9±12.18 mm
(Figure 34
volumes across all groups were n
significant difference in weight change over three weeks between any
(SE, SE-DEX10 and SE
33: T2 weighted MRI images in rats that have undergone status
s from a CTL rat
(a) and (b): L
-status
34b,
0.003). There was n
a). DEX appeared to be detrimental to total brain volume, however brain
controls.
and the second is from a
ow resolution images acquired
Shows significant atrophy of the hippocampus leading to
epilepticus rats (
p=0.01). SE rats had significantly lower relative hippoc
=0.001).
3 for CTL, SE, SE
-DEX2) (p=0.25).
95
The first column shows
ine respectively. (c) and (d): H
he regions of hyperintensity that occurred at 2
Figure
SE
o significant difference between SE
ot significantly different (p=
34c,d) using a multi
-DEX10 had significantly
3, 2565±12.3 mm
-DEX10 and SE
coronal MRI
rat that underwent status
at 48 h following
-
0.09).
igh resolution
-atlas approach.
lower rHCV
3, 2487.7±11.7
DEX2 respectively
There was no
of the groups
ampal
-DEX2
Figure
after status epilepticus
volume
group. (c) Example image showing automated segmentation of the
hippocampus in a control rat. (d) Example image demonstrating automated
segmentation of the hippocampus in a post
the initial insult. Treatment groups: CTL (n=4), SE (n=16), SE
SE-DEX2 (n=4).
34: Total brain volume and relative hippocampal volume at 3 weeks
vs. treatment group. (b) Relative hippocampal v
in rats treated with dexamethasone
96
-status epilepti
. (a) Total brain
olume
cus rat, 3 weeks after
-
vs. treatment
DEX10 (n=5),
97
Figure 35: Scatter plots showing the relationship between early T2
measurements and relative hippocampal volume measured 3 weeks after
SE. (a) and (b): Hippocampus and cingulate cortex T2 measured 2 days after SE
vs. rHCV. (c) rHCV vs. rHCV modelled using a linear mixed-effects model for
the data shown in (a) and (b). (d) Hippocampus T2 measured 4 days after SE vs.
rHCV. (e) rHCV vs. rHCV modelled using a linear mixed-effects model for the
data shown in (d).
6.7.6 Relationship between T2 and Hippocampal Volume
According to the linear mixed-effects model and considering all animals that
underwent status epilepticus, T2 in the hippocampus and the cingulate cortex at 2 d
following status epilepticus is predictive of relative hippocampal volume at 3 weeks
(Figure 35a,b) (β1=-0.00030±0.00007, 0.00031±0.0001, p=0.0004 and p=0.01
respectively). T2 at 4 d following status epilepticus in the hippocampus is predictive
of relative hippocampal volume (Figure 35d) (β1=-0.00035±0.00009, p=0.0007).
6.8 Discussion
The main findings from this study are that administering dexamethasone following
lithium-pilocarpine induced status epilepticus regionally intensifies acute T2
alterations at 2 days and 4 days following status epilepticus. Second, dexamethasone
adversely affects the degree of hippocampal injury at 3 weeks following SE. Third,
dexamethasone exacerbates the delayed mortality associated with status epilepticus.
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These findings apply even at doses of dexamethasone sodium phosphate as low as 2
mg/kg. Importantly, T2 relaxation times in the hippocampus were found to be
predictive of later hippocampal injury. Lastly, this study demonstrates that
quantitative T2 measurements and volumetric measurements in the rat can be
performed using automated methods that require no user intervention.
Previous studies have shown the T2 alterations following status epilepticus in the rat
peak at around 2 d following SE(44, 212), and this is confirmed in the current study.
Our previous work demonstrates that although there are significant changes in T2 in
the piriform cortices at 1 d following SE, T2 alterations in the hippocampus appear to
not be evident until 2 d following SE. Alterations in T2 occurring at this late time
point after SE could suggest that vasogenic oedema rather than cytotoxic oedema is
the primary cause of abnormalities throughout the hippocampus(213, 214). The
finding that T2 correlates with later hippocampal volume suggests that T2 might be a
useful biomarker for monitoring anti-inflammatory therapeutic interventions. The
current study supports a previous study revealing that T2 in the hippocampus at 2
days is predictive of later hippocampal volume(44).
This study has demonstrated that the acute T2 alterations that occur following
lithium-pilocarpine induced status epilepticus are exacerbated by DEX in the regions
already affected by SE. The design of the current study did not enable us to
determine whether these effects are due to side-effects of the drug such as
dehydration, alterations in plasma osmolality or blood pressure effects. No
relationship was found between treatment groups and the differences in body weight
between pre-SE and any of the subsequent days, suggesting that dehydration was not
the cause of the observed outcomes. It is also worth noting that the diuretic effect of
DEX in conjunction with its anti-inflammatory effect should help to alleviate
vasogenic oedema(207).
Unpredictably, a trend towards increased delayed mortality rate was observed in rats
treated with dexamethasone. The mechanisms behind delayed mortality following
status epilepticus are unknown. It has been speculated that it could be caused by
recurrent seizures(215). Vasogenic oedema is well known to contribute to death in
neurological disorders, therefore the increase in mortality in DEX treated rats
compared to the SE group could be attributable to increased brain oedema.
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Several possible explanations exist for the results observed. First, these data could
suggest that some early inflammatory processes may provide a protective effect,
which is not inconceivable given that there is an extremely fine balance between the
beneficial and detrimental effects of neuroinflammation(113, 216). Also notable is
that pre-treatment with COX-2 inhibitors has been observed to lead to increased
mortality both in electrically induced status epilepticus and in the kainate model(217,
218). This effect was likely due to aggravation of seizure activity, which is unlikely
to be the case in the current study given that previous data indicates that
dexamethasone suppresses pilocarpine induced SE(118). Further supporting the
hypothesis that early inflammation is protective, is a study which showed that
Interleukin-6 knockout mice exhibit reduced astrogliosis compared to wildtypes
following kainate induced seizures and this was accompanied by dramatically
intensified neuronal degeneration in the hippocampus(219). It is also noteworthy that
randomised controlled trials of anti-inflammatory therapies in patients with stroke or
traumatic brain injury (TBI) have observed an increase in mortality rate in patients
administered anti-inflammatory drugs compared to those given a placebo(220, 221).
One possible explanation for the worse outcome in TBI patients treated with
corticosteroids is that steroids have recently been shown to worsen cerebral oedema
under acidotic conditions in the rat(206). It is also likely that certain aspects of the
inflammatory process are protective whilst others are harmful. Further research is
required to explore this hypothesis.
An alternative explanation is that DEX could elicit a pro-inflammatory response. It
has been shown that glucocorticoids can exhibit pro-inflammatory effects under
certain conditions, e.g. chronic stress(222). Furthermore, corticosterone treatment has
been shown to exacerbate kainic acid induced neurotoxicity in the CA3 region of the
hippocampus and concomitantly increase the number of immunoreactive cells(223).
Given that the current study also reports a cerebral insult that is excitotoxic in nature,
possible pro-inflammatory effects of DEX might contribute to exacerbated brain
injury in DEX treated rats compared to saline treated rats.
Finally this study has demonstrated that automated methods of data analysis are
effective tools that can be employed in epilepsy research to reduce the laboriousness
of manual region drawing and therefore can be used in conjunction with
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histopathology to test the neuroprotective efficacy of new experimental treatments.
This is a noteworthy development as to our knowledge all other studies that have
attempted to measure hippocampal volumes in disease models have employed
manual segmentation.
6.9 Part III: Investigation into the Effects of Ethyl Pyruvate on Brain Injury
using Statistical Parametric Mapping
The result that dexamethasone exacerbated brain injury was surprising. For this
reason a different anti-inflammatory drug, ethyl pyruvate (EP) was tested. The
justification for using this compound was based on a previous study that
demonstrated EP to have noteworthy neuroprotective effects after kainic acid
induced seizures in mice(224). These protective effects were accompanied by a
reduction in microglial activation and remarkably they still occurred even when EP
was administered as late as 12 h after the insult. Suppression of microglial activation
and strong protective effects were also observed after ischemia-reperfusion injury
and effects were evident when EP was administered up to 24 h after the ischemic
insult(225). The reason for such late-acting effects is thought to be because EP
prevents the release of HMGB1, which as a late pro-inflammatory cytokine is
released only after a delay of around 12-18 h(226).
6.9.1 Aims
The design of this study is similar to the study design reported in the previous part.
The only differences are that relaxometry was only conducted at 48 h after the insult
and the later imaging time point was chosen to be approximately 2 weeks after SE.
The primary aim of this study is to test whether or not EP is effective at reducing
brain injury following SE. The secondary aim is to improve upon the imaging
techniques that are reported in part II. The secondary hypotheses in this study are:
- Voxel-wise statistical analyses (statistical parametric mapping (section 3.13))
should be used alongside region-based analyses for quantitative T2
measurements.
- Neuronal injury is not confined to the hippocampus after SE, therefore voxel-
based morphometry can be used to detect these more widespread changes.
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- Hippocampal volume measurements can also be achieved by the group-wise
registration afforded by VBM.
- 2D pulse sequences might be preferable to 3D sequences due to the greater
contrast that they afford (section 2.6).
6.10 Materials and Methods
6.10.1 Animal Model
All procedures and protocols were performed in agreement with the policies
established by the “Animal Care Committee” at Tohoku University, Sendai, Japan.
Status epilepticus was induced as described in section 5.3.1. 1 h after diazepam
administration, rats were randomly assigned to 1 of 2 groups, SE-EP (n=6) or SE
(n=6). Subjects in the EP group received 100 mg/kg ethyl pyruvate (28 mM) in a
calcium containing balanced salt solution made up of 130 mM sodium chloride, 4
mM KCl and 2.7 mM CaCl2 and the SE group received vehicle. The control group
(n=4) received saline in place of pilocarpine.
6.10.2 In vivo MRI
MRI was performed using a 7 T Bruker PharmaScan system (Bruker Biospin,
Ettlingen, Germany) and a 38 mm diameter bird-cage receive/transmit coil.
6.10.3 Relaxometry
T2 relaxometry was performed at 2 days after SE. Rats were anaesthetised with 4%
isoflurane in a 6:4 mixture of nitrogen and oxygen and were maintained on 1.5%
isoflurane throughout the imaging protocol. A multi-echo spin-echo sequence was
used with the imaging parameters: TR=3560 ms, TE=10.5, 21, 31.5, 42.1, 52.6, 63.1,
73.6, 84.2, 94.7, 105.2, 115.7, 126.3 ms, NEX=2, matrix=192×144, FOV=30×30
mm2, slice thickness=1 mm, number of slices=25. T2 maps were calculated using the
same curve fitting method outlined in section 6.6.1.
6.10.4 Volumetric MRI
High resolution 2D FSE imaging was performed 2 weeks after SE using the
following parameters: TR=4286 ms, TEeff=30 ms, ETL=4, NEX=8, matrix=256×256,
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FOV=32×32 mm2, slice thickness=0.6 mm, number of slices=50). The experimental
setup is described in section 7.9.2. Hippocampal volumes and total brain volumes
were measured using the methods described in sections 3.12 and 6.6.2 respectively.
6.10.5 Statistical Parametric Mapping
As noted in section 3.13, spatial normalisation can be used instead of atlas-based
segmentation. In this manner, statistics can be performed on a voxel-by-voxel basis
without prior hypotheses regarding the affected regions. All statistical parametric
mapping processing was done using SPM 8. First, (for the relaxometry data) a mean
volume was calculated by averaging across all echo times and this was segmented
into grey matter, white matter and CSF using probabilistic tissue priors (227), next
these binary images were spatially normalised using DARTEL (see section 3.13).
Following this, the T2 maps were spatially normalised by applying the corresponding
transformation matrix and deformation field. The normalised T2 maps were then
smoothed using a Gaussian filter with 0.5 mm FWHM prior to performing voxel-
wise t-tests. Because of the low number of subjects in each group, images were
displayed as p<0.05 (uncorrected for multiple comparisons) when comparing the
CTL and SE groups and p<0.01 for comparisons between the SE-EP and SE groups.
6.10.6 Voxel-based Morphometry
In order to increase the statistical power in comparing between the SE and CTL
group, an additional 4 CTL and 6 SE rats were imaged at the 2 week time point.
VBM was performed by firstly interpolating the FSE images between slices to
generate a final voxel size of 125×125×300 µm3 and then by segmenting the images
into grey matter, white matter and CSF using the SPM 8 Segment function and tissue
priors generated from normal adult rats(227). After this, population specific tissue
priors were generated using DARTEL. The images were then segmented again based
on the new tissue priors and again coregistered using DARTEL. This approach, in
which the segmentation procedure is performed using the population specific tissue
priors, is referred to as ‘optimised VBM’(228) and was used as standard VBM failed
to accurately segment the enlarged ventricles. Prior to statistical analysis, the
spatially normalised grey matter probability maps were smoothed with a 0.5 mm
FWHM Gaussian filter.
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Hippocampal volumes were also measured by manually segmenting the population
specific template. The deformation fields were inverted using DARTEL tools and the
results were used to transform the label image to the space of the original images.
6.10.7 Statistical Analysis
Statistical Analysis was performed in MATLAB using one-way ANOVA and two-
tailed t-tests assuming unequal variance. Statistical significance was assigned at
p<0.05. Correlation was expressed using Pearson’s product-moment correlation
coefficient r. SPM 8 was used for voxel-wise t-tests. Voxel-wise false discovery rate
(FDR) correction was used to control for multiple comparisons.
6.11 Results
6.11.1 Animal Model
All rats injected with pilocarpine progressed to status epilepticus. No rats died during
status epilepticus. 2 rats in the SE-EP group and 1 rat in the SE group died during the
first week after SE.
6.11.2 Relaxometry
In order to compare between the different groups, statistical parametric mapping was
used. In this case, two sample t-tests were performed at each voxel in the brain to
look for voxels which reached the significance level. The regions with significantly
higher T2 in SE subjects compared to controls can clearly be seen to be the piriform
cortex, amygdala, entorhinal cortex, hippocampus as well as subregions of the
thalamus and striatum (Figure 36). These regions agree well with those identified in
the previous experiment (Figure 32). Using statistical parametric mapping in this
case enables finer localisation of the affected regions. For instance, the CA1 region
appears to be the most affected subregion of the hippocampus. One control subject
was excluded from the analysis due to imaging artifacts. Unfortunately, this meant
that the low numbers in this group led to low power in the statistical analysis. The
mean T2 in the cortex in the CTL group was 67.7±2.4 ms, which is considerably
longer than T2 values reported at 7T in the literature(229).
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Figure 37: T-statistic maps of regions with higher T2 in SE rats compared to
SE-EP subjects. SE (n=6), SE-EP (n=6). P<0.01, uncorrected.
Figure 38: T-statistic maps of regions with higher T2 in SE-EP rats
compared to SE subjects. SE (n=6), SE-EP (n = 6). P<0.01, uncorrected.
6.11.3 Volumetric Measurements
There were no significant differences between the three groups in terms of body
weight (p=0.77) or total brain volume (Figure 39a) (p=0.38). There was a significant
difference in relative hippocampal volume between the groups (Figure 39b)
(p=0.00009). SE and SE-EP groups were both different from controls (p=0.001 and
p=0.0001 respectively)
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showed a significant loss in grey matter density. Small significant clusters were
observed in the right somatomotor areas (grey arrow). Only small subregions of the
thalamus displayed significant differences, for instance the ventral reuniens thalamic
nucleus (yellow arrow). The ventral tenia tecta (dark blue arrow) and infralimbic
cortex (dark green arrow) were affected as were the septum and regions surrounding
the lateral ventricles (light green arrow). Figure 40b displays the t-statistic map
thresholded with a value that corresponds to p<0.01, uncorrected for multiple
comparisons and displays more widespread differences throughout the hippocampus,
amygdala and neocortex.
Only two significant clusters survived FDR correction when comparing the
hypothesis that the grey matter density for the SE-EP is greater than the SE group.
These were in the hippocampus and neocortex but they only had a spatial extent of 3
and 4 voxels respectively. Because of their small cluster sizes and the low number of
subjects in each treatment group, these results were unlikely to be meaningful.
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Figure 40: T-statistic map of significantly lower grey matter density in SE
rats compared to controls, 2 weeks after SE. Arrow heads indicate anatomical
locations: CA1 (light blue), CA3 (orange), entorhinal cortex (purple), piriform
cortex (white), right somatomotor cortex (grey), ventral reuniens thalamic
nucleus (yellow), ventral tenia tecta (dark blue), infralimbic cortex (dark green),
septum (light green). T-statistic maps were overlaid on the normalised MRI
template and were thresholded at (a) voxel-wise FDR <0.05 and extent cluster
threshold>3 voxels and (b) p<0.01, uncorrected. CTL (n=8), SE (n=11).
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Figure 41: Agreement in hippocampal volume (HCV) measured by two
different methods: multi-atlas segmentation and segmentation propagation.
(a) Scatter plot showing the relationship between HCV measured via the two
methods for all subjects (n=23). (b) Bland-Altman plot showing average of the
two measurements plotted against the difference. Solid lines represent 1.96
standard deviations from the mean difference. (c)-(f) scatter plots only including
control subjects (n=8). (c) Total brain volume (TBV) vs. multi-atlas HCV (d)
TBV vs. segmentation propagation HCV. (e) Body weight vs. multi-atlas HCV.
(f) Body weight vs. segmentation propagation HCV.
6.11.5 Agreement in Hippocampal Volume Measurements
Hippocampal volumes can also be measured by the semi-automated segmentation-
propagation approach. This involves manually segmenting the group-wise template
generated from the VBM analysis and then inverting the forward displacement fields.
This inverse deformation was applied to the manually segmented label image to
transform it to the space of original images. Figure 41a shows that HCV
measurement via this method agrees well with the multi-atlas method shown in
Figure 39c,d, (r=0.94). The Bland-Altman plot (Figure 41b) shows that although
there was no evidence for a proportional bias (p=0.8), there was a systematic bias in
that the mean difference between the two measurements is 7.8 mm3. The 95% limits
of agreement (1.96 SD from the mean) are ±4.62 mm3, which indicates that there is
good agreement between the two methods given the range of measurements is
approximately 23 mm3. The multi-atlas HCV and the segmentation-propagation
HCV correlated with total brain volume in the control group (Figure 41c, r=0.93,
p=0.001 and Figure 41c, r=0.9, p=0.002 respectively). Body weight correlated with
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HCV for the multi-atlas method (Figure 41e, r=0.77, p=0.02) but was not significant
for the segmentation-propagation method (Figure 41f, r=0.65, p=0.08).
6.12 Discussion
This study demonstrates that spatial normalisation and statistical parametric mapping
can be used in order to localise differences between groups without the need for
predefined anatomical labels and can therefore be used as a sensitive method of
therapy monitoring if used in combination with meaningful parameters. The T2
mapping in this study was subject to artifacts and therefore could not be used to
determine conclusively whether EP reduced SE associated cerebral oedema.
Nevertheless, the voxel-based relaxometry approach presented here shows that acute
T2 changes in the lithium-pilocarpine model affect certain subregions more than
others therefore region-based approaches may be subject to reduced sensitivity and
partial volume effects. Although the number of subjects was low, there was no
evidence that EP was neuroprotective or detrimental based on hippocampal volume
measurements. These results are contradictory to the results in a previous study that
showed EP to be strongly protective against kainate induced seizures in mice(230)
but could be attributed to the differences in the animal models or differences relating
to the time point of drug administration. In the current study, the drug was
administered 1 h following termination of SE, whereas Cho et al. administered the
drug 12 h after the seizure. On the other hand, in the rat cerebral ischemia model the
efficacy of the drug decreases with the time period between the insult and drug
administration(231).
This is the first attempt to perform VBM in the rat lithium-pilocarpine model of
epilepsy. One of the main strengths of VBM lies in its ability to identify very
localised differences between groups. Regional differences in grey matter
concentrations were found throughout the limbic regions as well as very localised
parts of the thalamus, prefrontal and neocortex. Brain injury is not limited to the
hippocampal formation in the lithium-pilocarpine model therefore grey matter
density measurements using optimised VBM might be useful for assessing the
efficacy of neuroprotective therapies. Alongside this VBM could be used to explain
differences in cognitive impairment across animals and between groups. There are
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some limitations of VBM that should also be noted here. One of these is that
differences in grey matter density might result from a number of reasons and as such
lower grey matter density might not be limited to neuronal loss. It could also be
attributed to almost any biological change that results in abnormal signal intensity in
T2 weighted images and might be caused by gliosis in this model. Another limitation
of VBM is that when brains are severely pathological, e.g. in subjects with enlarged
ventricles, this could result in misclassification of tissue classes and the tissue classes
being represented by an erroneous distribution of intensity values. This problem has
been alleviated in the current work by using optimised VBM.
Group-wise registration using DARTEL method was also used to calculate
hippocampal volumes and there was found to be good agreement between this and
the multi-atlas method. A comparison was not made between these techniques and
the gold standard i.e. manual segmentation. However, the stronger correlation in the
control group between multi-atlas HCV, brain volume and body weight suggests that
this method is superior to semi-automated segmentation-propagation.
Finally, this study found that 2D pulse sequences can also be used for the assessment
of brain injury following SE as illustrated by the dramatic difference in rHCV
between the Control and SE groups at just 2 weeks after SE. Using 2D sequences
may enable shorter scan durations and therefore the possibility of using a larger
number of subjects in preclinical therapy studies than would be possible with lengthy
3D acquisitions. Another advantage of 2D imaging is that it can be less sensitive to
motion as the acquisition time is shorter and phase encoding, which is sensitive to
motion is only performed in 1 direction. Longer TRs can be used in 2D sequences
with the result that the acquired images are more T2 weighted and therefore have
greater contrast between grey matter, white matter and CSF. The main disadvantage
is that the resolution in the slice direction is much lower, therefore the positioning of
the imaging volume needs to be performed more accurately. In the future, the
presence of multiple receiver coils and sensitivity encoding(232) could be used to
circumvent these issues so that 3D imaging can be used to its full potential.
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6.13 Conclusions
In conclusion, the first part of this chapter attempted to show that the corticosteroid
dexamethasone could be used to modulate the expression of VCAM-1 and hence
modulate the molecular imaging biomarker outlined in the previous chapter.
Although the number of animals was low in these pilot studies, there was no
evidence that this drug was able to modulate VCAM-1 expression. The second part
of this chapter attempted find out if early dexamethasone treatment following SE
could alleviate brain injury. It was shown that even low doses of dexamethasone
worsen the regional effects that status epilepticus has on the brain. This may be a
forewarning that if anti-inflammatory drugs such as corticosteroids are to be used in
clinic during or following childhood status epilepticus as has been advocated(82), the
type of drug and time course of administration are likely to be crucial. In the last part
of this chapter, the anti-inflammatory drug ethyl pyruvate was tested for its potential
as a neuroprotective agent. This drug was chosen as previous studies have shown that
its efficacy is less sensitive to the time course of administration than other anti-
inflammatory drugs due to its mechanism of action in which it suppresses the late
inflammatory cytokine HMGB1. Little evidence was found to say that this drug was
neuroprotective in the lithium-pilocarpine model. Despite this, data in this study were
used to perform voxel-wise T2 comparisons and voxel-based morphometry and was
used to establish that these voxel-wise methods can be used in combination with
volumetric imaging to provide information across the whole brain that is not
restricted to predefined regions.
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Chapter 7 Functional Connectivity
7.1 Aims
The preceding chapter demonstrated the power of structural MRI to detect seizure-
induced brain injury and monitor neuroprotective strategies. The current chapter is
concerned with seizure-induced changes in brain function and will test the hypothesis
that functional connectivity is disrupted after status epilepticus.
7.2 Introduction
Functional connectivity (FC) can be defined as temporal correlations between
spatially remote neurophysiological events(233). Functional connectivity is a useful
concept as direct neuroanatomical connectivity does not necessarily imply
correlations in neural activity and vice versa. Measuring neurophysiological events
over time can be achieved using EEG, MEG (magnetoencephalography) or
functional MRI (fMRI), albeit with different time resolutions for each of these
methods. Recently it has been realised that measuring functional connectivity can be
a powerful tool that can be used to aid in our understanding of the brain and its
pathological states.
Even in the absence of prescribed tasks, the brain exhibits reproducible and
measurable correlation in activity between different regions(234). This task-
independent activity has been termed the ‘resting state’. Since this initial finding,
there has been an explosion of interest in resting state functional MRI (rsfMRI),
particularly in relation to understanding neurological diseases. Partly this interest has
been fuelled by the convenience of the technique as it requires no experimental
paradigm. The next section will describe how a technique called fMRI can be used as
a surrogate marker for neuronal activity and the following sections will be concerned
with how this has been used to observe FC in the epileptic brain.
7.3 Haemodynamic Response to Neural Activity
Local increases in neural activity can be indirectly detected using fMRI. The contrast
mechanism in fMRI is thought to involve increases in energy demand which drive
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local increases in cerebral blood flow. Alterations in blood flow in response to
increases in energy demand is known as the haemodynamic response.
Deoxyhaemoglobin is paramagnetic and therefore higher concentrations lead to
faster dephasing of magnetisation. Reductions in the concentration of
deoxyhaemoglobin in the blood therefore cause an increase in signal intensity on
gradient-echo (or spin-echo) images. This is the basis of the blood oxygen level-
dependent (BOLD) contrast mechanism(235). Increases in neural activity leads to a
haemodynamic response, which brings about an oversupply of oxygenated blood. As
the supply in oxygenated blood exceeds demand, the result is a decrease in venous
deoxyhaemoglobin levels, which leads to an increase in T2* and therefore higher
signal intensity on gradient echo images. Typically, the peak of stimulus-induced
haemodynamic response is known to occur several seconds after the stimulus and
fast imaging sequences such as echo-planar imaging (section 2.5) can be used to
image events on this timescale.
7.4 Analysis of Resting State fMRI Data
As rsfMRI is a relatively new technique and as such there has yet to be a consensus
on the most appropriate method of generating inferences about functional
connectivity. Typical approaches fall under 4 different categories: seed-based
correlation, ROI-based correlation, independent component analysis and graph
theoretical approaches. These will be discussed in turn in the following sections.
7.4.1 Seed-Based Correlation
Seed-based correlation involves selection of a seed time course. This can be defined
as the time course from an individual voxel, or the average time course across a ROI.
This time series is then correlated to every other voxel in the brain. Using a seed-
based method represents more of a hypothesis-driven approach to rsfMRI analyses.
As noted by Constable et al., a reasonable starting point in epilepsy patients might be
to use the suspected seizure focus as a seed ROI(236) to observe how its role has
changed in the functional network.
115
7.4.2 ROI-Based Correlation
A ROI-based approach typically refers to correlating the time courses generated from
pairs of ROIs. Clearly the difficulty with this method lies with the designation of the
regions. A natural choice would be to use the anatomical regions as defined by an
atlas. The danger with this approach is that it is possible that these anatomically
defined regions do not represent functional regions, therefore other methods to define
ROIs typically employ the use of task-based fMRI or independent component
analysis, whilst more recent approaches use the voxel time series themselves to
define ROIs(237).
7.4.3 Independent Component Analysis
Independent component analysis (ICA) represents a ‘model-free approach’ to the
analysis of rsfMRI data. There are two major issues associated with using ICA, the
first is that the number of components needs to be fixed at an estimated or an
arbitrary value, and second that there is no consensus yet as to how to select
components of interest. Typical methods to achieve component selection involve
correlation with an atlas and/or measures involving the power spectrum of the time
series(238).
7.4.4 Graph Theory
Graph theory-based approaches enable the quantitative characterisation of functional
networks as a whole. Using graph theory the brain is modelled as a set of nodes
which represent brain regions, and edges which represent the relationship between
the nodes. In rsfMRI, the nodes can be defined as ROIs or as individual voxels and
their edges can be characterised by how well the nodes correlate with one another.
Weighted graphs have weights or distances associated with each of the edges e.g. the
edge weights can be defined as the pairwise correlation efficient or these can be
thresholded to give an unweighted graph. Given a set of nodes, edges and weights,
several metrics can be calculated and the more commonly used ones will be briefly
outlined below.
The degree of a node characterises how strongly it is connected to the rest of the
graph and is defined as the number of edges directly connected to it. The connection
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between two nodes i and j can be denoted as aij. Let aij=1 if nodes i and j are
connected and aij=0 if otherwise. The degree (d) of node i can then be defined as
d(i)=Ʃjaij. The strength of a node (in a weighted graph) also measures how closely a
node is associated with the rest of the graph. It can be defined as the sum of all
connection weights to a node i.e. the strength (s) of node i is defined as: s(i)=Ʃjwij,
where wij is the weight of the edge between node i and j.
The average path length is a measure of how efficiently information is transferred
across a network and is defined as the number of steps along the shortest path
between any two nodes averaged across the entire graph. The clustering coefficient
expresses the extent of local interconnectivity(239). For an unweighted graph it is the
fraction of all possible nodes that exist within the neighbourhood of a node. For
weighted graphs, a commonly adopted formula is the one derived by Onnela et
al(240).
Constable et al. have recently reviewed the use of resting state fMRI in patients with
partial epilepsy(241). This review discusses approaches to analysis that are based on
correlation and graph theory. The authors conclude that modelling the entire degree
distribution of each voxel in a fully connected graph can be used to summarise
information about connectivity, thus taking into account both enhanced and reduced
functional connectivity and at the same time circumventing the need for setting
arbitrary thresholds for correlation coefficients in order to decide whether an edge
exists or not. The measure that is proposed is termed the intrinsic connectivity
distribution(242).
7.5 Functional Connectivity in Epilepsy
The interest in functional connectivity in the context of epilepsy stems from the fact
that epilepsy is a network-based disorder. It is thought therefore that resting state
fMRI could be used to predict outcomes following surgery in intractable epilepsy,
the localisation of epileptogenic foci or predict the development of epilepsy. As the
technique is relatively new, most studies to date have focussed on identifying
differences between patient groups and controls. Despite rsfMRI being relatively free
from experimental paradigms, comparisons between studies are hugely problematic
because of the large range of preprocessing and analysis methods used.
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Using the medial temporal structures as seeds for a seed-based correlation analysis,
Pittau et al. found that patients with unilateral mTLE have decreased connectivity
with the contralateral healthy mesial temporal structures(243). Bettus et al. found
that left mTLE patients had decreased connectivity between the ipsilateral entorhinal
cortex and the anterior hippocampus accompanied by increased connectivity between
the contralateral anterior and posterior hippocampus(244). In patients with bilateral
HS, Liao et al. observed significant increases in functional connectivity within the
medial temporal structures and decreased connectivity within and between the frontal
and parietal lobes(245). This study found patients to have abnormal graph theory
metrics(7.4.4), such as a lower degree of connectivity, lower clustering coefficient
and shorter path length compared to controls. Another study used graph theory
metrics and supervised classification in order to elucidate the differences between
mTLE patients and control subjects. Using a method of feature selection that is
resistant to overfitting, they found it was possible to distinguish patients from
controls with a sensitivity of 77% and a specificity of 83%(246). The most
discriminating features were reduced strength and closeness of the right hippocampal
node. Their study was based on a heterogeneous sample including patients with both
right TLE and left TLE and therefore possibly underestimated the power of rsfMRI
to distinguish patients from controls.
7.6 Resting State fMRI in Animal Models
The challenges involved in performing fMRI in rodents are typically greater than
those in human studies, partly due to the need for stable physiology under
anaesthesia. Many different anaesthetics have been tested for rsfMRI experiments
and it is well-established that the pattern and strength of connectivity depends on the
anaesthetic used. Recently, medetomidine(247, 248) or dexmedetomidine(249) have
become the most popular choices for rsfMRI experiments. Studies that have used
isoflurane suggest that functional connectivity shows a surprising dependence on the
level of anaesthetic administered. Functional connectivity increases across the
sensorimotor regions as the level of isoflurane is increased from 1% to 1.8%(250),
but above 1.8%, spontaneous EEG activity is suppressed along with the
synchronicity of the fMRI signal(251). Compared to medetomidine, rsfMRI
experiments under 1.5% isoflurane exhibit higher ‘background’ correlations across
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the whole brain and therefore seed-based correlations can be seen to exhibit much
more widespread and less regional FC than under medetomidine(247). For this
reason, medetomidine is frequently preferred over isoflurane for rsfMRI studies in
rodents. Using ICA (section 7.4.3), Jonckers et al.(252) identified 9 meaningful and
reproducible resting state ‘networks’ in rats anaesthetised with medetomidine, which
were named based on their anatomical locations. These 9 components were: the
motor cortex, somatosensory cortex, auditory cortex, retrosplenial cortex,
hippocampus, striatum, cingulate cortex, visual cortex and inferior colliculus.
Only a handful of studies investigating functional connectivity in animal models of
epilepsy have been reported. One such study looked at global network measures in
the tetanus toxin rat model. In this model, tetanus toxin is administered to the right
primary motor cortex. This manifests as spontaneous seizures for several weeks.
Graph analysis showed an increase in global clustering coefficient and path length in
the tetanus treated group which was accompanied by a decrease in interhemispheric
connectivity(253).
7.7 Preprocessing of Images
Prior to any statistical analysis that is performed on fMRI data, there are several
preprocessing steps that should be performed in order to attempt to remove sources
of signal change that are not linked to haemodynamic changes. In reality, this is
extremely difficult due to the inherent low signal-to-noise ratio of the technique. A
typical sequence of pre-processing normally involves some or all of the following
steps: brain extraction (masking), slice-timing correction, realignment (motion
correction), unwarping (distortion correction), coregistration to an anatomical
volume, normalisation to a standard space, regression of nuisance variables and
spatial and/or temporal filtering. The following section will focus on realignment,
nuisance variables and temporal filtering.
7.7.1 Realignment
Realignment is necessary as there is normally subject motion throughout the fMRI
acquisition. Even in the situation in which there is no subject motion, changes in
resonance frequency resulting from subject respiration could result in voxel shifts
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along the phase encoding direction(254). This can be extremely problematic as small
movements can cause large changes in signal intensity and it is commonplace to
reject datasets that are unusable due to excessive motion. Realignment is usually
performed using rigid registration to one of the images or to the mean image. This
assumption that head motion occurs in a rigid manner is known to be flawed due to
issues with slice timing(255). The realignment function in SPM8 was found to
reduce the coefficient of variation (SD/mean) of a region in a single slice from
0.0236 in the raw data to 0.0226 post-realignment if performed on the entire 3D
volume. However, the coefficient of variation was increased to 0.0237 if performed
on the same single slice suggesting that multislice data is necessary for realignment
to be performed.
7.7.2 Nuisance Variables
It is often assumed in fMRI studies that signals in the white matter and CSF are
derived from non-neuronal sources e.g. physiological sources, scanner noise and
motion etc. As these are of no interest in FC studies, they can be removed using
regression so as not to lead to artificially high correlations in FC data. Global signal
is also sometimes regressed out, however it is thought that this practice generates
anti-correlations and therefore should not be used(256). It is also possible that there
exists some collinearity between the nuisance variables, therefore orthogonalisation
is sometimes performed prior to the linear regression. This is possible via the
Gram-Schmidt process.
7.7.3 Temporal Filtering
Signals of interest in rsfMRI fall within the 0.01-0.1 Hz frequency range(234). Low-
pass filtering of time series is often employed to minimise signal contributions from
physiological sources. Slow alterations in signal (<0.01 Hz) are likely to be caused
by changes in temperature or heart rate of the subject(248) or due to scanner
instability(257). Removing low frequency drift can be achieved by detrending e.g. by
fitting a low degree polynomial function to the data and retaining the residuals of the
fit.
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7.8 Study Design
In this study, it was hypothesised that status epilepticus leads to alterations in
functional connectivity that can be detected using rsfMRI. Imaging was performed 2
weeks after the initial seizure in order to allow time for some degree of
epileptogenesis to occur in SE rats. Longitudinal imaging was not possible due to the
need for neuromuscular blockers. Isoflurane was chosen as the anaesthetic because
even though medetomidine is typically the preferred anaesthetic (see section 7.6),
previous studies in the department were performed under isoflurane and so the same
protocol was used in order to allow for comparisons between these data. Furthermore,
it is known that isoflurane suppresses seizure-like activity, which is not the case for
medetomidine(258). The data included in this study were acquired as part of the
same imaging session as the longitudinal imaging described in section 6.10.4.
Prior to performing the rsfMRI experiment, a forepaw stimulation experiment was
performed using alpha-chloralose as the anaesthetic. The purpose of this experiment
was to ensure that the imaging protocol and hardware was stable enough to be able to
measure BOLD signal changes. Alpha-chloralose was used in this experiment as
isoflurane is known to suppress the BOLD response under the conventionally used
stimulation paradigm(259).
7.9 Materials and Methods
All procedures and protocols were performed in agreement with the policies
established by the “Animal Care Committee” at Tohoku University, Sendai, Japan.
7.9.1 Forepaw Stimulation
In order to ensure that a BOLD signal response could be measured using the
proposed imaging setup, a forepaw stimulation experiment was performed under
alpha-chloralose anaesthesia. The anaesthetic protocol was previously optimised by
Dr Sumiyoshi at Tohoku University(260) and consisted of a bolus injection of 80
mg/kg followed by continuous infusion (20 mg/kg/h, i.v.) of alpha-chloralose via a
cannula inserted into the lateral tail vein. The animal was intubated and mechanically
ventilated as in section 7.9.2. Pancuronium bromide (2 mg/kg/h, i.v.) was
continuously infused via the tail vein cannula for muscle relaxation and reduction of
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motion artifacts. A physiological monitoring system (SA Instruments, Stony Brook,
NY) was used to monitor rectal body temperature. Temperature was maintained at
37±0.5°C using a water tubing warming system. Forepaw stimulation was performed
by insertion of a pair of needle electrodes into the left forepaw. A block design was
used with 10 blocks with each block comprising of 30 s stimulation and 40 s rest.
Stimulation was implemented at a rate of 3 Hz, with a current of 2 mA and a pulse
width 0.3 ms using a pulse generator (SEN-3401, Nihon Kohden) and isolator (SS-
203J, Nihon Kohden). The SPM 8 t-test function was used to test the hypothesis that
the stimulation condition > rest condition. For display purposes t-statistic maps were
thresholded at p<0.01, family-wise error rate (FWE) corrected with a cluster extent
threshold of 5 voxels. Gradient-echo EPI was used for functional imaging with the
same parameters as in section 7.9.2.
7.9.2 Resting State fMRI
Rats were anaesthetised with 4% isoflurane in a 6:4 mixture of nitrogen and oxygen
and were maintained on 1% isoflurane throughout the imaging protocol. The tail vein
was cannulated and rats were intubated with a 19 gauge plastic cannula. Mechanical
ventilation was performed at 60 breaths per minute with a tidal volume of 6-6.2 ml
(SAR-830/AP, CWE Inc., Ardmore, PA, USA). Pancuronium bromide (2 mg/kg/h)
was continuously infused via the tail vein cannula. Rats were secured in the MRI
scanner using a bite-bar and surgical tape. A physiological monitoring system was
used to monitor rectal body temperature. Temperature was maintained at 37±0.5°C
using a water tubing warming system. Resting state fMRI was performed using a 7 T
Bruker PharmaScan system (Bruker Biospin, Ettlingen, Germany) and a 38 mm
diameter bird-cage receive/transmit coil. Shimming was at first instance done over
the entire field of view and then over a voxel located in the brain using FASTMAP.
fMRI was conducted using gradient-echo echo-planar imaging with the following
parameters: TR=2 s, TE=15 ms, slice thickness=1.5 mm, matrix=70×35, number of
volumes=300, dummy scans=4.
7.9.3 Spatial Normalisation
The average EPI image across all time points from each dataset was firstly
interpolated in the slice direction to give a final voxel size of 400×400×750 µm. and
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then brain extracted using the approach described in section 3.10 and then rigidly
coregistered using NiftyReg to an EPI template using 6 free parameters(261).
Following this, the new population specific mean image was calculated and each
dataset was registered to this mean image using a 12 parameter affine registration.
Registration to the mean image was performed 4 times and the mean image was
updated after each iteration in order to create the population specific EPI template.
The EPI data were transformed to this template using the calculated transformation
matrices and were then smoothed in SPM 8 using a Gaussian filter of 0.8 mm full
width at half maximum (FWHM).
7.9.4 Independent Component Analysis
Group ICA was performed using the Infomax algorithm in the GIFT toolbox
(http://www.nitrc.org/projects/gift/). The default parameters were used and the
number of components was fixed at 20. The weights of voxels for each ICA
component were considered as random variables and a 1 sample t-test was performed
in SPM 8 to test the null hypothesis that these weights significantly deviate from zero.
These t-statistic maps were thresholded at p<0.01, uncorrected for multiple
comparisons.
7.9.5 Seed-based Correlation
The nuisance covariates, which included the 6 realignment parameters and white
matter time courses were orthogonalised with respect to each other using the Gram-
Schmidt process. The data are displayed with and without including the global signal
across the entire brain as a nuisance covariate. Each time series was normalised to
have a mean of zero and unit variance and was detrended with a second order
polynomial and filtered using a third order low pass Butterworth filter with a 0.1 Hz
cutoff frequency. Seed-regions were chosen from the right cerebral hemisphere. Four
regions were manually drawn on the normalised EPI template which included: the
anterior hippocampus, thalamus, primary somatosensory cortex forelimb region and
caudate putamen. The mean time-course across each region was correlated to every
voxel in the brain using the Pearson product-moment correlation coefficient (r). For
hypothesis testing, correlation coefficients were transformed using Fisher’s r-to-z
transformation.
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7.9.6 Graph Theory Measures
Time courses were extracted from 20 different manually segmented regions: both
right and left cingulate cortex (CG), primary motor cortex (M1), primary
somatosensory cortex (S1), secondary somatosensory cortex (S2), caudate putamen
(Cpu), anterior dorsal hippocampus (HippoAD), posterior hippocampus (HippoP),
piriform cortex (Pir), corpus callosum (CC) and thalamus (Thal). Preprocessing was
performed as in section 7.9.5, without global signal regression and each region was
correlated to every other region to generate a correlation matrix. The correlation
matrices for each subject were used as the weighted adjacency matrices. These
matrices were not thresholded and so fully connected graphs were constructed. Two
graph theory measures, strength and clustering coefficient were calculated using the
brain connectivity toolbox(262) (https://sites.google.com/site/bctnet/). In order to
obtain measures that are independent of differences in correlation across the entire
network, 1000 surrogate random networks were calculated by randomly shuffling the
edge weights and graph theory measures were normalised to the measures averaged
over all 1000 random networks.
7.9.7 Statistical Analysis
(a) Graph Theory Measures
Statistical analysis was conducted on the normalised graph theoretical measures by
using two-tailed randomisation tests. T-statistics were compared to the permutation
distribution. The permutation distribution was found by calculating the t-statistic for
10000 random permutations of the dataset. Statistical significance was assigned at
p<0.05. Correction for multiple comparisons was performed using the Benjamini-
Hochberg procedure for false discovery rate (FDR) control(263).
(b) Seed-based correlation
Statistical analysis on seed-based correlation maps was performed without having
removed the global signal component from the data as recommended by Gotts et
al.(264). Hypothesis testing was done using two-sample t-tests in SPM 8 assuming
unequal variance. Statistical significance was assessed on a voxel-wise basis using
FDR<0.05 and a 3 voxel cluster extent threshold.
7.10 Results
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pH pCO2 (mmHg) pO2 (mmHg) % O2 sat
CTL before 7.42 41 103 97.8
CTL after 7.43 38 111 98.2
SE before 7.36 45 103 97.5
SE after 7.375 43 100 97.4
Table 1: Physiological parameters from arterial blood sampling before and
after the rsfMRI experiment.
7.10.3 Motion Parameters
The average maximum displacement in any direction over the duration of the scan
was 0.062±0.09 mm and 0.064±0.1 mm for the control and epilepsy group
respectively (p=0.9). The maximum displacement was not greater than 0.12 mm (less
than one third of a voxel) in any subject therefore no subjects were excluded from the
analysis.
7.10.4 Independent Component Analysis in the Control Group
Group ICA was conducted only in the control group as an exploratory data analysis
tool and out of the 20 fixed ICA components, 6 appeared to be ‘meaningful’ based
on their time courses, interhemispheric symmetry and consistency with the
literature(252). As noted in section 7.4.3, there is no well-established method to
select ICA components and as such this is often carried out subjectively. These 6
components are displayed in Figure 43 for networks containing the: (a) striatum, (b)
cingulate cortex, (c) somatosensory and motor cortex, (d) hippocampus, (e) thalamus
and (f) piriform and entorhinal cortices.
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When global signal is regressed out (Figure 45), seed-based correlation maps appear
to be remarkably similar between the two groups. As to be expected, the correlation
maps with global signal regression resemble the group ICA components (Figure 43).
With exception to the somatosensory seed region (Figure 45c,d), correlation maps
from all seed regions exhibit clear correlations to the same contralateral brain
structure.
7.10.6 Comparison between the Control and SE groups
T-tests were used to compare the two groups on the Fisher z transformed correlation
maps. Only the anterior hippocampus and thalamus showed any significant voxels
after FDR correction. Significantly reduced correlation can be observed in the SE
group compared to controls using the hippocampal seed region. This reduced
correlation can be seen in regions that are confined to the ipsilateral and contralateral
hippocampus, piriform cortex, cingulate cortex, contralateral hypothalamus,
entorhinal cortex and limited regions of the ipsilateral somatosensory cortex (Figure
46). Functional connectivity from the thalamus is reduced in regions that are
confined only to the hypothalamus, ipsilateral cortex and ipsi- and contralateral
piriform cortex (Figure 47). Remarkably, t-statistic maps comparing the two groups
can be seen to exhibit a large degree of bilateral symmetry.
Figure
regression.
and the right column shows rats that underwent status epilepticus 2 weeks prior
to imaging (n=11). All seed regions were chosen from the right cerebral
hemisphere. (a)
region, (e)
Correlatio
44: Mean seed
Left column show
-
-(f) anterior hippocampus (g)
n maps are thresholded at
-based correlation maps without global signal
(b) caudate putamen, (c)
128
s maps averaged across all control subjects (n=8)
-(h) thalamus and (
r=0.1.
-(d) somatosensory cortex forelimb
i)-(j) piriform cortex.
Figure
Left
right column shows rats that underwent status epilepticus 2 weeks prior to
imaging (n=11). All seed regions were chosen from the right cerebral
hemisphere. (a)
region, (e)
Correlation maps are thresholded at
45: Mean seed
column shows maps averaged across all control subjects (n=8) and the
-
-(f) anterior hippocampus (g)
-based correlation maps with global signal regression.
(b) caudate putamen, (c)
129
-(h) thalamus and (i)
r=0.1.
-(d) somatosensory cortex forelimb
-(j) piriform cortex.
130
Figure 46: T-statistic map comparing the hypothesis that: CTL>SE for z
correlation maps using the right anterior hippocampus as a seed region.
Significance was assessed using voxel-wise FDR<0.05 and cluster extent
threshold>3 voxels. CTL (n=8), SE (n=11).
Figure 47: T-statistic map comparing the hypothesis that: CTL>SE for z
correlation maps using the right thalamus as a seed region. Significance was
assessed using voxel-wise FDR<0.05 and cluster extent threshold>3 voxels.
CTL (n=8), SE (n=11).
7.10.7 Graph Theory Measures
The regions identified using ICA were identified, manually segmented on the EPI
atlas and used in a graph theoretical analysis. The somatomotor regions were
subdivided into M1, S1 and S2 and the hippocampus was divided into anterior and
posterior.
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No significant differences were observed in the global graph theory measures
between the two groups. The normalised mean clustering coefficient across the
whole network was 1.034±0.006 for controls and 1.026±0.007 for the SE group and
the normalised average path length was 1.077±0.01 for controls and 1.076±0.01 for
the SE group.
The unnormalised strength of all ROIs is higher in control subjects than the SE group
(Figure 48a). Unnormalised strength in the white matter should be minimal because
these signals were used as nuisance covariates. However, strength in these regions is
closer to 1 than 0 as the right and left corpus callosum are strongly correlated with
each other. Following normalisation no graph theory measures survived the FDR
correction for multiple comparisons, therefore all p-values reported here are
uncorrected. Strength is lower the SE group compared to controls in the right anterior
hippocampus (p=0.01), left piriform cortex (p=0.02) and right thalamus (p=0.03)
Figure 48d). The normalised clustering coefficient (NCC) was lower in the left
piriform cortex in the SE group compared to controls (p=0.02). NCC was also lower
in the right hippocampus and right thalamus but these did not reach statistical
significance (p=0.06 and p=0.05). NCC was higher in the right motor cortex
compared to controls (p=0.02).
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Figure 48: Graph theory measures in CTL and SE subjects. The first
column shows unnormalised measures and the second column shows measures
normalised to a surrogate random network. (a) Strength, (b) normalised
strength, (c) clustering coefficient, (d) normalised clustering coefficient.
Unnormalised strength and clustering coefficient is lower in the SE group. After
normalisation, the strength is lower in the SE group in the right anterior
hippocampus (HippoAD R), left piriform cortex (Pir L) and right thalamus
(Thal R) compared to controls. Clustering coefficient was lower in the left
piriform cortex but higher in the right motor cortex (M1 R) compared to
controls. CTL (n=8), SE (n=11). Descriptive error bars are displayed as
±SEM.
7.11 Discussion
The main finding from this study is that differences in resting state fluctuations can
be observed following lithium-pilocarpine induced SE. These occur primarily within
the limbic regions but the thalamus and cortex are also affected. However, there are
several limitations of this study that need to be addressed.
7.11.1 Study Limitations
Even though there was no significant difference in body weight between the two
groups, it is possible that any differences between groups are caused by differences
in systemic physiology. This is a limitation of the current study. However, the
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physiology of the measured subjects was within the normal limits suggesting that the
results are not artifactual. Another limitation of this study is that EEG was not
measured therefore it is unknown whether any undesirable interictal spiking was
present. Despite this, it is well known that isoflurane anaesthesia suppresses seizures
as well as spikes in brain activity. Finally, the SE group had significant hippocampal
volume loss (section 6.11.3). Although regions of CSF can largely be avoided when
drawing ROIs, such a large and varying degree of atrophy may mean the
coregistration to the EPI template might not perform as well for some of the MRI
volumes in the SE group.
7.11.2 Independent Component Analysis
The functional connectivity networks identified using ICA agrees well with the
literature. The striatal, sensorimotor, cingulate and hippocampal networks have also
been observed by Jonckers et al.(252) under medetomidine. Kalthoff et al.(247),
found that compared to medetomidine, the incidence of cortical and striatal networks
is reduced in rats anaesthetised with 1.5% isoflurane. Similar to the current study,
they also found no clear segregation of striatal and sensorimotor networks under
isoflurane. In rats anaesthetised under 1% isoflurane, Hutchison et al.(265) observed
all but one of the resting state networks that were found in the current study and to
our knowledge, the component involving the piriform cortex has not previously been
reported in the literature. This could be due to the fact that all other studies in rodent
rsfMRI have employed surface receiver coils that exhibit steep drop-offs in
sensitivity towards the ventral surface of the brain. The current study utilised a
birdcage receiver coil that has a more homogeneous sensitivity across a larger
imaging volume. In addition, Hutchison et al. found segregation of the primary,
secondary, somatosensory and motor cortices. This was not observed in the current
study but this could be because the number of components in their ICA analysis was
fixed at twice the number of the current study.
7.11.3 Seed-based correlation
Previous studies in rats anaesthetised with isoflurane have demonstrated widespread
correlation in seed-based analyses(266), which largely agrees with the results in the
current study. In this study, significant reductions in functional connectivity were
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found in the SE group compared to controls. Interestingly, the regions of reduced
correlation are most dramatic in the regions that are known to be affected in the
lithium-pilocarpine model e.g. the piriform cortex, entorhinal cortex, hippocampus
and thalamus. This agrees with rsfMRI studies on mTLE patients which have found
reduced correlation between the hippocampus and most other networks(267) as well
as a more widespread disruption across most functional networks(268).
7.11.4 Graph Theory
There are only a few studies that have looked at FC in models of epilepsy. A study in
the tetanus toxin rat model found increases in global normalised clustering
coefficient and average path length(253), which contrasts with the current study as
no difference in the global clustering coefficient or average path length could be
observed here. However, the analysis method in the current study was different in
that anatomical regions rather than single voxels were used as nodes.
Strength was lower in the right hippocampus, left piriform cortex and right thalamus
in SE rats compared to controls, which shows some agreement with the seed-based
analysis in which significant decreases in correlation were found in the SE group. In
the graph-theory analysis, differences between groups were only observed
unilaterally. This contrasts with the seed-based analysis and is difficult to reconcile
with the structural imaging data which suggests alterations in this model are nearly
always bilateral. The seed-based analysis highlights differences in functional
connectivity between the two groups, whereas the significant differences did not
survive correction for multiple comparisons in the graph theory analysis. This could
be because averaging the signal over such large anatomically defined regions might
eliminate some of the signals of interest and that ROIs should be smaller in order to
characterise the FC network. Data-driven approaches, such as ICA, might be
preferable and enable more functionally relevant designation of nodes than using
anatomically defined boundaries.
7.11.5 Possible Explanations
There is a large degree of atrophy 2 weeks after lithium-pilocarpine induced SE
(section 6.11.4). Therefore, it is possible that disruption in functional connectivity in
the current study is partly due to neuronal loss or even a departure from normal
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metabolism interfering with the haemodynamic response. On the other hand,
significant decreases in correlation were observed between the thalamus and the
neocortical regions, which are relatively preserved in this model (section 6.11.4).
Atrophy in one brain region might also lead to widespread dysfunction in brain
networks(268). In general, the effects of structural damage on functional connectivity
are largely unknown(267). Such severe atrophy could obscure abnormal increases in
functional connectivity and this might explain the discrepancy between increases in
interictal synchronicity on EEG and decreases in fMRI in epilepsy subjects(269).
7.12 Conclusions
To our knowledge, this is the first study to observe differences in functional
connectivity in the lithium-pilocarpine model of temporal lobe epilepsy. Significant
reductions in correlations were observed in seed-based analyses from hippocampal
and thalamic seed regions. These reductions occurred in the regions that are known
to be affected in this model and exhibit noteworthy bilateral symmetry. Future work
will be necessary to determine the relationship between functional connectivity
measures, cognitive impairment and the development of epilepsy.
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Chapter 8 Conclusions and Further Work
Chapter 1 summarised the dramatic progress that has been made in recent years in
identifying new targets for anti-epileptogenic therapies. It also emphasised that
finding biomarkers for therapy monitoring and epileptogenesis will be crucial in the
search for new therapies. Recent advances in imaging methods have enabled the real
possibility of identifying these biomarkers and it is almost certain that animal models
and in vivo preclinical imaging will be instrumental in this pursuit.
Chapter 4 and Chapter 5 show that using iron oxide contrast agents for molecular
imaging of VCAM-1 could be used as a meaningful biomarker for monitoring anti-
inflammatory therapies. Using these contrast agents, Chapter 5 outlines the first
demonstration of non-invasive imaging of VCAM-1 in an animal model of status
epilepticus. As iron oxide is non-toxic and biodegradable there is potential that these
iron oxide contrast agents can be used in a clinical setting either for therapy
monitoring or for selecting suitable patients to undergo treatment. Several challenges
will have to be overcome before this will be feasible. First, the biodistribution studies
reported in Chapter 4 show that these particles may aggregate in vivo and become
trapped in pulmonary vasculature. It was also found that blood clearance of micron-
sized iron oxide particles is extremely rapid. Altering the physicochemical properties
particles or coating with hydrophilic polymers could lead to improvements in
contrast agent kinetics. Another approach to improve the sensitivity and specificity
of these agents might be to use different targeting moieties, such as antibody
fragments or peptides. Pretargeting strategies could be used, in which the contrast
agent is conjugated to the targeting moiety in vivo using the biotin/streptavidin
interaction. This pretargeting approach could prove to be especially advantageous for
nuclear imaging in which high background signal could obscure the signal of interest.
The first part of Chapter 6 outlines experiments that attempted to use molecular
imaging for the purpose of therapy monitoring. Anti-inflammatory therapies were
administered after status epilepticus and imaging of VCAM-1 was performed 1 day
later. These attempts at therapy monitoring proved unsuccessful i.e. there was no
evidence that the anti-inflammatory drug dexamethasone reduced expression of
VCAM-1. These results were extremely surprising but could be because
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dexamethasone given acutely after SE does not modify expression of VCAM-1.
Because of these unsuccessful attempts at therapy monitoring, follow-up experiments
were planned which aimed to utilise more well-established imaging biomarkers for
this purpose. T2 relaxometry and volumetric imaging were chosen for this purpose
because they are well accepted markers of oedema and brain injury.
Before starting a longitudinal study based on acquiring high resolution 3D images.
The problems of data analysis needed to be considered. In order to ascertain
volumetric measurements, image segmentation is required, which can be
prohibitively laborious if this is attempted using manual methods. For this reason,
automated methods of segmentation were employed.
Multi-atlas based segmentation was used for automated hippocampal volume and
total brain volume measurements. Before being using to assess the drug therapies, it
was first cross-validated and the results of this are displayed in Chapter 3. Chapter 6
shows that using well-established MRI techniques such as relaxometry and
volumetric approaches can be coupled with automated analysis methods to
efficiently screen neuroprotective strategies in vivo and longitudinally.
Imaging methods offer advantages over purely histological studies as they allow
access to 3D data and to longitudinal data. If these imaging methods are combined
with automated analysis methods, they can also be less labour intensive and cost
effective. Longitudinal studies require fewer animals compared to cross-sectional
studies and its wider adoption will hopefully lead to a reduction in the number of
animals used in basic research and drug development in the future.
Using these automated analysis techniques, dexamethasone was tested for its ability
to reduce brain injury following SE. The data conclusively demonstrated that
dexamethasone had detrimental effects at two different doses. Furthermore,
dexamethasone regionally exacerbated early brain oedema as well as delayed
mortality. These data are feasible given recently published data in a rat model of TBI
showing corticosteroids to exacerbate oedema when brain tissue is acidotic(206).
This effect was found to be mediated by aquaporin-1 (ACP-1), as giving ACP-1
blockers reduced this effect. It would be interesting to determine if blocking ACP-1
also reduces this effect in the lithium-pilocarpine model.
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Under non-acidotic conditions, Tran et al. found that dexamethasone improves
oedema(206). Therefore a natural extension of the work presented in Chapter 6
would be to determine whether dexamethasone can be seen to have beneficial effects
for SE of a shorter duration. This study could also determine if there is a relationship
between outcome (after administering corticosteroids) and arterial blood pH levels.
Another simple experiment could be performed to determine whether dexamethasone
exacerbates or reduces the brain’s inflammatory response by immunohistochemical
staining for reactive astrocytes (glial fibrillary acidic protein). Given the worsening
of oedema found in Chapter 6, it is likely that leakage of serum proteins will cause a
worsening of gliosis and might even exacerbate the development of epilepsy.
The final part of Chapter 6 applies the aforementioned techniques to test another
anti-inflammatory compound - ethyl pyruvate, which also did not prove to be
efficacious in the rat lithium-pilocarpine model. Part III of Chapter 6 further
discusses why spatial normalisation and voxel-wise statistics should be conducted
alongside region-of-interest based approaches. The reasons for this are that brain
injury in this model is not localised to the hippocampus so that hippocampal
volumetry should be combined with voxel-based approaches. Another reason for
using voxel-based approaches is that certain subregions are affected much more than
others therefore region-based methods are likely to be less sensitive due to partial
volume effects. Chapter 6 displays the first demonstration of voxel-based
morphometry in an epilepsy animal model. VBM is based on a unified approach to
tissue class image segmentation i.e. the bias field and the tissue classes are modelling
in the same framework. It is extremely sensitive for detecting abnormal signal
intensities, but this strength is also a limitation as the biological changes that are the
basis for these abnormalities may be hard to interpret. New implementations of the
SPM segmentation algorithm will make it possible to incorporate multispectral data
(e.g. T1, T2, mean diffusivity etc.) as prior information and therefore they could
improve the specificity of the technique.
The discrepancy in the literature between the efficacies of different anti-
inflammatory drugs is disconcerting. The results depend to a large extent on which
model of epileptogenesis is used and the time course of drug administration. This is
exemplified by the recent study by Noe et al.(122) who coadministered the ICE
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inhibitor - VX765 and an interleukin-1 receptor antagonist after electrically induced
SE. They found this combination therapy to be neuroprotective in the electrical SE
model but found there to be almost no effect in the lithium-pilocarpine model. They
explained these findings by the more dramatic inflammatory response (number of IL-
1β positive astrocytes) in the lithium-pilocarpine model. An extension of the work 
presented in this thesis would therefore be to test the effects of corticosteroids or EP
in the electrically induced SE model. The effects of the combination treatment
reported by Noe et al. appear to be regional i.e. the drug was most effective in the
neocortex and CA1 region of the hippocampus. Therefore another possible future
study could be to use a similar drug combination in the electrical SE model to
determine whether voxel-based imaging methods can be used to detect these regional
differences in treated and untreated groups in vivo.
Corticosteroids are currently used as a last-resort treatment in cases of super
refractory status epilepticus(270). Further basic research will be necessary to
determine whether these or other anti-inflammatory drugs should be translated to the
clinic as a neuroprotective strategy. It is encouraging that studies which have found
drugs to have limited or no efficacy are published. Despite this, there is a culture of
not publishing negative results which may be ethically problematic if these same
drugs are to be translated to the clinic and it is likely that a publication bias exists
towards studies which have found positive outcomes(271, 272). Partly, this
publication bias may arise from the need to ensure a rigorous safeguarding against
type II errors(273).
Finally, as a component of the same study outlined in Chapter 6, functional
connectivity is explored in Chapter 7. Although there has been rapidly expanding
interest in applying resting state fMRI to patients with epilepsy, there has been a
dearth of preclinical studies in this area due to the immense challenges involved.
Preclinical studies should be able to disentangle the confounding factors from real
effects in studies on functional connectivity. The study reported in Chapter 7 found
reduced correlation in the SE group between the anterior hippocampus and the limbic
regions of the brain as well as parts of the neocortex. Significant decreases in
correlation were also observed between the thalamus and the piriform cortex along
with similar regions of the cortex. It is possible that these findings were as a result of
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the significant neuronal injury that is present at this time point in the lithium-
pilocarpine model. Further analysis is required to determine the relationship between
structure and function. More experimentation will be necessary to determine whether
rsfMRI will be useful in predicting cognitive deficits or epileptogenesis.
For the purpose of predicting epileptogenesis, molecular imaging is likely to be one
of the most powerful techniques available. On the other hand it is less clinically
translatable compared to the already approved imaging methods. In the near future,
currently available techniques should be employed to assess the feasibility of
predicting brain injury and epilepsy. For example, intrinsic image contrast in MRI,
(such as T1, T2, mean diffusivity etc.) could be coupled with voxel-based imaging
methods and long-term electrophysiology to determine which parameters are
predictive of SRS. A study of this nature has recently been reported by Kharatishvili
et al.(63). An extension of their work would be to use more powerful supervised
learning algorithms with better validation approaches to determine the
generalizability of the model.
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